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During the last decade, HIV in sub-Saharan Africa has shifted from a fatal disease to a 
chronic condition thanks to the expansion of antiretroviral therapy (ART). As a result, the 
focus of care has transitioned from survival to quality of life (QoL), and the latter has 
become a significant outcome measure during patient follow up. Yet, the determinants of 
QoL among HIV patients in western and central Africa are not well known. 
The objective of this dissertation was to determine the main factors associated with QoL 
among ART-treated HIV adult patients in western and central Africa to ensure healthcare 
providers and stakeholders use the most relevant, up-to-date evidence when designing and 
implementing interventions that help patients effectively stay in care and remain 
asymptomatic. 
We first performed a systematic review to synthesize known determinants of QoL in sub-
Saharan Africa. Leveraging the findings of the systematic review, we conducted a cross-
sectional survey at Espoir Vie Togo (EVT), a patient-oriented community health clinic in 
Lomé, Togo, to measure QoL and determine which factors previously identified in the 




population. We also interviewed EVT patients to better understand their life experiences and 
potentially uncover novel factors associated with QoL. 
The systematic review included 41 observational studies conducted in 14 countries and we 
found that QoL was most frequently influenced by sociodemographic factors such as age, 
education, gender, employment, social or family support, as reported in nine or more studies; 
by clinical factors including mental health and CD4 count; and treatment-related factors such 
as treatment duration. 
At EVT, the mean (SD) physical health summary (PHS) and mental health summary (MHS) 
scores of 147 ART-treated patients were 80.7 (13.9) and 66.7 (11.1), respectively, on a 0-100 
scale. Younger age, male gender, food security, the absence of side effects and self-evaluated 
“excellent” or “very good” health status were associated with higher PHS scores. Male 
gender, a higher level of education, food security, family or social support and self-evaluated 
“excellent”, “very good” and “good” health status were associated with higher MHS scores.  
Finally, in qualitative interviews with 12 ART-treated EVT patients, patients described good 
QoL as being in good health and being physically and mentally functional. Family, social and 
community support, the presence of a supporting individual, being on ART and food security 
were factors influencing QoL. In this cohort, participants experienced difficulties accepting 
their positive status, and often faced perceived or enacted stigma. 
The QoL of people living with HIV in western and central Africa is driven by multiple 
sociodemographic, clinical and treatment-related factors that have been summarized in this 
dissertation. These findings provide stakeholders with valuable evidence to optimize patient 




treatment satisfaction between patients receiving care in non-governmental organizations and 
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The HIV/AIDS epidemic has been a major public health challenge in sub-Saharan Africa 
for several decades. At its peak in 2005, the number of AIDS-related deaths in sub-Saharan 
Africa was 2.4 million, and in 2002, only 50,000 individuals were receiving life-saving 
antiretroviral therapy.1,2 However, the launch of the “3 by 5” initiative in 2003 by the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization 
(WHO) set out to provide 3 million doses of life-saving antiretroviral therapy (ART) to people 
living with HIV (PLHIV) in low- and middle-income countries by the end of 2005.3 That initial 
campaign and subsequent ambitious treatment goals led to a significant increase in the number of 
HIV positive individuals receiving ART, as well as a decrease in AIDS-related deaths and 
consequently, an increase in HIV prevalence.4 In fact, an estimated 15.4 million PLHIV in Africa 
were receiving ART in 2017 and 670,000 died from AIDS-related causes, representing a 42% 
reduction in AIDS-related mortality from 2004 to 2017 in eastern and southern Africa, and a 
24% reduction in western and central Africa.5,6,7  
Thus, HIV has shifted from a fatal disease to a chronic condition, and as the life 
expectancy of PLHIV continues to increase and becomes similar to that of the general population 
in some cases, quality of life (QoL) is emerging as a significant medical outcome in HIV 
management.8 WHO defines QoL as “an individual's perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns.”9 In the context of HIV as a chronic disease, QoL has 
become an essential part of follow up assessments. Measuring QoL is key to documenting the 
burden of disease, monitoring changes in health, evaluating the efficacy of ART, and analyzing 





more likely to adhere to treatment11 and thus reduce virologic failure and drug resistance, which 
have been shown to be associated with poor adherence to ART.12  
 
HIV Infection: Epidemiology, Pathogenesis and Treatment 
 
Epidemiology: An estimated 37.9 million people were living with HIV globally in 2018, and 1.7 
million were newly infected.13 In low- and middle-income countries, 62% of adults and 54% of 
children living with HIV were receiving life-saving ART.13 The most affected region is the 
WHO African region, with 25.7 million PLHIV and approximately two thirds of new HIV 
infections globally.13  
 HIV results from the animal-to-human (zoonotic) transfer of a simian immunodeficiency 
virus.15 There are two main types of HIV. HIV type 1 (HIV-1) is the most common type, and it is 
classified into four subtypes. Subtype M (major) is responsible for the global HIV epidemic. 
Within subtype M, there are nine genetically distinct strains (A, B, C, D, F, G, H, J, K), which 
are found in different geographic areas. Nearly fifty percent of all PLHIV globally have strain C, 
and it is highly prevalent in eastern and southern Africa.15 The subtypes N (new), O (outlier) and 
P are uncommon and restricted to western and central Africa. In Togo, 99.1% of PLHIV have 
HIV type 1.58  
HIV-2 is mainly prevalent in western Africa. It causes an illness similar to HIV-1 but it is 
less infectious, and an HIV-2 infection progresses more slowly and results in fewer deaths.15,16 
The different HIV types found in western and central Africa compared to eastern and southern 
Africa thus result in differential risks of transmission, disease progression and quality of life 





HIV infection is mainly acquired through unprotected sexual intercourse, mother-to-child 
transmission, and exposure to infected blood through needles, syringes, or transfusion.14 The 
dominant modes of transmission differ according to geographical regions. In high-income 
countries, male-to-male sexual contact is the main mode of transmission whereas vaginal 
intercourse and mother-to-child transmission are dominant in developing countries.15,16 
Individuals at increased risk for HIV infection (i.e. key populations) include men who have sex 
with men, injection drug users, inmates, sex workers and transgenders.13 
Prevention and treatment are the two current strategies for dealing with the epidemic. Successful 
prevention consists of persistent and continuous behavior change interventions, especially in key 
populations; a clear understanding of the needs of target populations; and empowering 
individuals most at risk.14 There is currently no cure for HIV, but ART effectively controls the 
virus and prevents transmission by reducing the viral load to an undetectable level, and it is 
increasingly becoming accessible to HIV patients in developing countries. 
 
Pathogenesis: HIV is a retrovirus belonging to the lentivirus genus.14 Its genome is less than 10 
kilobases and although it only encodes 16 viral proteins, it is able to successfully counter the 
human immune system.17 Like most viruses, HIV uses host cells to replicate itself and produce 
new HIV copies. HIV’s life cycle lasts one to two days, and consists of seven well-documented 
stages:14-17  
Binding: HIV’s main envelope proteins, glycoprotein (gp)-120 and gp41, bind to CD4 receptors 
on the surface of T lymphocytes (also known as T cells) or macrophages, both of which are 





coreceptors (i.e. CCR5 when the target cell is a macrophage, or CXCR4 when the target cell is a 
T cell).  
Fusion: HIV’s membrane fuses with the target cell’s membrane and HIV releases its viral RNA, 
reverse transcriptase, integrase, and protease into the cell’s cytoplasm.  
Reverse transcription. Reverse transcription mediated by viral reverse transcriptase begins and 
allows viral RNA to be converted into single-stranded DNA, then into double-stranded DNA 
after replication. 
Integration: Viral DNA enters the cell’s nucleus and is inserted into the cell’s DNA by viral 
integrase. 
Replication: The newly formed DNA produces messenger DNA that initiates the synthesis of 
HIV proteins, which are building blocks for the formation of more HIV. 
Budding: Viral RNA, HIV proteins and components needed to make new viruses gather at the 
cell’s membrane and push out of the cell to form virions, immature HIVs that contain all the 
components necessary to infect new target cells after maturation. 
Maturation: Viral protease cuts HIV proteins into smaller functioning proteins, which combine to 
form the viral core of the virus. The virus is now mature and can infect other cells. 
 
Stages of Infection: Without treatment, HIV-infected individuals naturally progress through 
three stages of disease, which correspond to the level of viral replication.18 
Stage 1 - Acute HIV infection: Infected individuals may experience a flu-like illness within two 
to four weeks after infection. This illness may last for several weeks and it corresponds to the 
immune system’s response to the infection. The immune system is not yet producing HIV 





Stage 2 - Clinical latency: HIV infection is chronic or asymptomatic for most patients, and HIV 
replicates at low levels. Without treatment, this stage may last a decade or more although some 
individuals may progress faster. Individuals may not show signs of illness or have any 
symptoms. Patients under ART are virally suppressed and are less likely to transmit the 
infection. The end of this phase is characterized by an increasing viral load and a decline in 
CD4+ cell count. 
Stage 3 - Acquired immunodeficiency syndrome (AIDS): HIV patients are diagnosed with AIDS 
when their CD4 count is <=200 cells/mm³ or when they acquire AIDS-defining conditions (also 
known as opportunistic illnesses) such as Kaposi sarcoma, Burkitt lymphoma, or recurrent 
pneumonia. The immune systems of AIDS patients are highly damaged, and they have high 
plasma viremia with high rates of HIV replication. They are also highly infectious and may 
experience symptoms such as swollen lymph nodes, weight loss, and weakness. Without 
treatment, the life expectancy is three years.  
 
ART and current treatment options: There is currently no cure for HIV, however, antiretroviral 
medications are available to help patients live healthier and longer lives. In fact, standard ART, if 
taken correctly and regularly, prevents or slows the progression of HIV, and leads to a significant 
reduction in HIV morbidity and mortality.14  
The therapeutic goals of ART include long-term suppression of HIV replication, immune 
function restoration, and improvement in quality of life.14 Treatment efficacy is measured 
through the reduction of opportunistic illnesses, the increase of CD4+ cell count and the decrease 





HIV patients may experience treatment failure, in which case the combination of antiretroviral 
medications is changed according to guidelines. 
ART is given daily as a combination of different classes of antiretroviral agents capable of 
stopping HIV at different key steps of its life cycle. The initial regimen usually includes three 
antiretroviral drugs from at least two different drug classes.19  
There are seven antiretroviral drug classes, classified according to how they interfere with the 
virus:  
1) nucleoside reverse transcriptase inhibitors (NRTIs) block reverse transcriptase and prevent 
the transcription of viral RNA into DNA.19  
2) non-nucleoside reverse transcriptase inhibitors (NNRTIs) also block reverse transcriptase. 
3) protease inhibitors (PIs) block viral protease and prevent new HIV maturation.  
4) fusion inhibitors block HIV from fusing with CD4 cells hence prevent HIV from entering the 
cell. 
5) CCR5 antagonists block the CCR5 coreceptors on the surface of T cells.  
6) post-attachment inhibitors block HIV from binding to CCR5 and CXCR4 coreceptors. 
7) integrase strand transfer inhibitors (INSTIs) block viral integrase thus prevent viral DNA 
from inserting into the host cell’s DNA. 
WHO’s current recommendations are to start HIV-infected individuals on ART as soon as 
possible after diagnosis.20 The most current WHO standard guidelines, dated July 2019, are 
based on accumulated scientific evidence and experience from diverse HIV programs worldwide. 
They recommend starting newly-infected adults and adolescents initiating first-line ART on 





[3TC] (or emtricitabine [FTC])). An alternative first line regimen is efavirenz [EFV] 400 mg in 
combination with TDF + 3TC.21 
When failing a first-line DTG-based regimen, atazanavir/ritonavir (ATV/r) or 
lopinavir/ritonavir (LPV/r)) in combination with two optimized NRTIs (zidovudine [AZT] + 
lamivudine [3TC]) is recommended for second-line ART. An alternative second-line regimen is 
DTG in combination with AZT + 3TC or with TDF + 3TC (or FTC), if DTG was not taken as a 
first-line drug.21  
First- and second-line regimens differ for children and neonates, for whom approved DTG 




Previous research assessing the QoL of HIV patients treated with ART exists, however, 
most studies quantitatively assess QoL scores without searching for potential factors affecting 
those scores.22,23 Studies that do investigate the predictors of QoL among PLHIV have been 
mostly conducted in high-income countries (in the US, Finland, Spain, Ireland, South Korea, and 
Iran) and in eastern and southern Africa (in Rwanda and Uganda).24-32 In those regions, several 
determinants of improved QoL have been identified, including socio-demographic factors (i.e. 
male gender, younger age, high socioeconomic status, being employed) and clinical factors (i.e. 
lower viral load, higher CD4 cell count).24-32 Those studies also suggest that taking ART and 
treatment adherence remain the two key factors associated with improved QoL.33  
There is a lack of evidence on the determinants of QoL in western and central Africa, 
where HIV prevalence and incidence rates are significantly lower compared to eastern and 





of the difference of HIV type associated with the epidemic that results in a differential 
progression of the disease.14,34,35 In 2017, of the 25.7 million PLHIV in sub-Saharan Africa, 19.6 
million (77%) lived in eastern and southern Africa (out of an estimated population of 597 
million)36 while 6.1 million (33%) lived in central and western Africa (estimated population of 
436 million).36 Moreover, there were 800,000 new HIV infections in eastern and southern Africa, 
compared to 370,000 in western and central Africa.35 Thus, generalizing findings from studies 
conducted in eastern and southern Africa to western and central Africa may not be appropriate, 
and it is preferable to assess trends and patterns in each region separately in order to better 
interpret and understand research findings.  
Because of the aforementioned historical, cultural and religious particularities, as well as 
specificities of the epidemic and the paucity of research, there is a need for a comprehensive 
assessment of factors affecting QoL in central and west African HIV patients.34 A previous 
cross-sectional study evaluated QoL and depression in 200 ART-treated Senegalese patients but 
did not search for an association.37 Another cross-sectional study investigating QoL among 158 
HIV-positive patients in rural Ghana found that being a female, sexually active, asymptomatic 
and treated with ART were associated with higher QoL scores.38 Further, a cross-sectional study 
of 491 Nigerian PLHIV found that being ≥40 years old was associated with the environment and 
spirituality domains of QoL, being married with social relationship, self-reporting a “good” or 
“very good” health status with all domains, a CD4 cell count ≥350 cells/mm3 with the physical, 
psychological and level of independence domains, and being on ART for more than 18 months 
with the psychological, level of independence and spirituality domains of QoL. Unfortunately, 





What these studies have in common is that they used previous literature as the source of 
risk factors for their investigation. Although it is common practice in epidemiological research, 
this results in the same demographic and clinical variables being repeatedly assessed, and this 
does not allow new factors to be investigated. A systematic review can be used to synthesize and 
systematically identify risk or protective factors from diverse and scattered publications, then 
analyze them comprehensively. This method will help detect under-investigated yet significant 
factors associated with QoL. 
In 2014, Degroote conducted a literature review to identify determinants of QoL in 
PLHIV in high-income countries and although a few studies drew conflicting results, the author 
reported that overall, certain socio-demographic characteristics (i.e. male gender, younger age, a 
stable relationship, employment, and higher education) were associated with higher QoL.40 
Moreover, clinical factors such as better virological status, starting ART at CD4 <200 cells/µl, 
early HIV stage, and the absence of HIV-related symptoms or comorbities were also associated 
with higher QoL. Finally, psychological factors including depression, anxiety, HIV status 
disclosure and stigma were negatively associated with QoL whereas social support was 
positively associated. Although Degroote identified several factors associated with QoL, their 
review may not be generalizable to sub-Saharan Africa, which is fundamentally different from 
high-income countries in many aspects, notably in the social and molecular epidemiology of the 
epidemic.41 
Two systematic reviews geographically restricted to sub-Saharan Africa analyzed QoL 
among PLHIV receiving ART. One (Beard 2009) assessed the effect of ART on QoL, mental 
health, labor productivity, and economic wellbeing.42 This review found ART to be associated 





domains of QoL. Concerning work-related outcomes, performance improved, and absenteeism 
decreased in patients receiving ART. Unfortunately, factors associated QoL other than ART 
were not investigated. The other review (Robberstad & Olsen 2010) first reported a synthesis of 
eight studies quantitatively assessing QoL in PLHIV for economic evaluations purposes, then 
described the findings of a focus group of HIV clinicians on EuroQol-5D (EQ-5D), a QoL 
instrument measure, and its use in low-income settings.43 The authors did not seek to identify 
factors associated with QoL. 
Hence, a systematic review summarizing risk or protective factors associated with QoL 
among sub-Saharan African populations would address the current gap in knowledge. 
Subsequently determining which of these factors is associated with QoL would help improve 
patient wellbeing, and more importantly improve ART adherence, given that treatment 
adherence is a key factor associated with higher QoL, as previously mentioned.33. Given the 
current importance of QoL in HIV management, healthcare professionals can benefit from 
additional insight on the risk factors causing HIV patients to fall out of care. The consequences 
of loss to follow up due to poor QoL among patients who started ART are detrimental, not only 
for the patients themselves but also in terms of potential spread of the infection and in the 
success of ART programs in sub-Saharan Africa.44 
In addition to investigating the relationship between risk or protective factors and QoL, 
this dissertation attempted to further examine the qualitative aspect of QoL research among 
PLHIV in western and central Africa. Several qualitative studies have been conducted in this 
region to better understand perceptions of QoL among PLHIV, and we believed that including a 
qualitative component to this dissertation may contribute to gain additional knowledge on factors 





(2014) interviewed HIV patients and asked them to define QoL, and what their perception of 
QoL was.45 The author reported that their description was similar to that of the World Health 
Organization. More interestingly, her research allowed for the discovery of indicators of QoL as 
perceived by HIV patients, such as happiness, food availability, shelter or availability of money. 
A similar approach can be undertaken in our dissertation to allow participants to discuss QoL 
issues that may affect their lives, and potentially lead to the discovery of indicators of QoL in the 
social and cultural context of western and central Africa. 
 
Public Health Significance 
 
The management of HIV as a chronic disease requires lifelong therapy and sustained 
care, mainly to ensure continued adherence to ART and rapid adjustments as treatment failure 
arises.46 This requires well-honed and well-resourced healthcare delivery systems, which are 
often lacking in sub-Saharan Africa. However, the lack of efficient healthcare systems at the 
national level can be balanced by excellent patient care at the community clinic level. Knowing 
that over 1.1 million individuals in sub-Saharan Africa were newly infected in 2017, treating 
those individuals early and retaining them in care would contribute to their achievement of viral 
suppression, which is one of the key steps of UNAIDS’s 90-90-90 treatment target to end the 
AIDS epidemic by 2020 (i.e. by 2020, 90% of PLHIV will know their HIV status, 90% of those 
infected will receive sustained ART and 90% of those receiving ART will have viral 
suppression).35,47 Retaining patients in care is a major challenge in sub-Saharan Africa, and one 
significant way to overcome it is to ensure patients maintain a high QoL as they cope with their 





allow healthcare providers and stakeholders to act upon them and ensure patients effectively stay 




The following aims will help determine the main factors associated with QoL in ART-
treated PLHIV in west and central Africa. 
Aim 1: Conduct a systematic review to identify the main factors associated with 
standardized quality of life measures in ART-treated HIV adult patients in sub-Saharan Africa. 
Aim 2a: Measure the quality of life of HIV patients receiving long-term ART in a 
community health clinic in Togo. 
Aim 2b: Assess the association between main socioeconomic, clinical and treatment-
related factors identified in the systematic review and physical and mental domains of QoL in 
patients of a community health clinic in Togo, after adjusting for demographic variables. 
Aims 3: Identify indicators of quality of life as described by ART-treated HIV patients of 








 The first part of this dissertation was a systematic review with the aim to identify key risk 
or protective factors associated with QoL in sub-Saharan Africa. 
 
Prior Systematic Reviews and Registration 
 Prior systematic reviews on this topic were searched for, first on the Texas Medical 
Center library website using the following search term: (hiv OR aids) AND (“Quality of Life” 
OR QOL OR HRQoL) AND (sub-Saharan Africa) AND (“systematic review” OR “meta-
analysis”), second on Medline, by combining the following search terms: (hiv OR human 
immunodeficiency virus OR aids OR acquired immunodeficiency syndrome), (quality of life OR 
health-related quality of life OR QOL OR HRQoL), exp “Africa South of the Sahara”/ and 
(systematic review OR meta-analysis), and finally on PubMed using search terms similar to 
Medline’s.  
An additional search was conducted on PROSPERO, the international database for 
registering systematic reviews. To ensure the most comprehensive and complete search possible, 
only “HIV” was used for the search. 33 HIV-related reviews were found. We reviewed them 
individually to assess whether a review of the association between risk or protective factors and 
QoL in HIV patients was already registered. No previous review matching our methodology was 







 Study participants for the systematic review were sub-Saharan HIV-positive individuals 
aged 18 years or older who were taking antiretroviral therapy. Following the PICOTS principle, 
participants were “HIV-positive individuals aged 18 years or older”, intervention was 
“antiretroviral therapy”, comparator was “any” or “none”, outcome was “any quality of life 
assessment obtained using a standardized questionnaire or instrument (such as World Health 
Organization Quality of Life-HIV [WHOQOL-HIV], Medical Outcomes Study HIV Health 
Survey [MOS-HIV], EQ-5D, 36-Item Short Form Survey [SF-36], etc…), including an adjusted 
analysis assessing an association between risk or protective factors and QoL”, time was “any”, 
setting was “sub-Saharan Africa” and study design was “randomized or non-randomized 




Our systematic review was conducted following Methodological Expectations for 
Cochrane Intervention Reviews (MECIR) standards.48 A systematic search from inception to 
May 2019 was conducted on Medline, PubMed, Embase and PsycINFO to identify studies for 
inclusion. In addition, non-databases sources, including GreyNet, Grey Literature Report and 
BIOSIS Previews, were searched for grey literature such as meeting abstracts, posters and 
unpublished articles. 
Our search strategy was tailored for each database. It combined HIV, quality of life and 
sub-Saharan Africa terms as shown in Appendix A for Ovid Medline, Appendix B for PubMed, 







Two independent screeners (Oubote Sangbana, Peter Elyanu) performed a title/abstract 
screening in order to exclude studies not meeting the pre-determined criteria.  
Exclusion reasons during screening were age <18 years old, not HIV-positive, not in sub-
Saharan Africa, does not include ART, does not include QoL outcomes, does not include a 
standardized QoL instrument, not an original study, not a clinical study, animal study, or in vitro 
study. Cohen’s Kappa was calculated to assess interrater reliability, and areas of disagreement 
between the two screeners was resolved by consensus. Following the title/abstract screening 
phase, a full text review phase was performed in order to select studies reporting outcomes of 
interest. The primary outcome was a QoL assessment from a previously validated questionnaire 
(eg. WHOQOL, MOS-HIV, EQ-5D, SF-36). The secondary outcome was any risk or protective 




A brief data collection form was created after selecting studies meeting the inclusion 
criteria. One reviewer (OS) extracted all data of interest listed in the form using an excel 
spreadsheet. A second reviewer (Akira Look) reviewed the extracted data for errors. 
Disagreements were resolved by consensus. Per Cochrane recommendations, items to collect 
from each selected study included data related to the source, eligibility, methods, participants, 
interventions, outcomes, and key findings.49 Most importantly, it included the factors associated 
with improved or reduced QoL. A risk or protective factor was selected and retained for the 
second part of this dissertation if was statistically significantly associated (p<0.05) with overall 





An evidence table was created to summarize and present characteristics and key findings from 
each study. It included the author’s name, country, study dates, sample description, QoL 
instrument, risk or protective factors, and key findings. 
 
Preliminary rapid scoping review 
To assess the feasibility of our systematic review, we conducted a preliminary rapid 
scoping review, and 12 studies meeting our inclusion criteria were identified (data not shown). 
Potentially extractable risk or protective factors affecting QoL are shown in table 1. 
 
Table 1. Potential variables of interest from a preliminary focused literature review. 
 
 
Variable  Format 
Demographics 
Gender  Male, Female 
Age  Continuous (years) or Categorical 
Education Level  None, Primary, Secondary or more 
Employment Status  Student, Employed, Unemployed, Other 
Marital Status  
Single, Married or Partner, Separated/Divorced, 
Widowed 
Health-Related 
Duration of treatment  Continuous (months) or Categorical 
Regimen  1st Line, 2nd Line, >=3rd Line 
Treatment adherence  Yes, No 






Sexually Active  Yes, No 
Self-Perceived as Healthy  Yes, No 
Time Since HIV  Continuous (months) 
Clinical 
Viral Load  Continuous (copies/mL) or Categorical 
CD4+ count  cells/mm3 
HIV/TB co-infection  Yes, No 
Treatment-related adverse events  Yes, No 





Risk of Bias 
The risk of bias for each included study was assessed using National Institutes of Health 
(NIH)’s 14-item quality assessment tool for observational cohort and cross-sectional studies.50 
The 14 questions were: 
1. Was the research question or objective in this paper clearly stated?          
2. Was the study population clearly specified and defined?          
3. Was the participation rate of eligible persons at least 50%?          
4. Were all the subjects selected or recruited from the same or similar populations (including the 
same time period)? Were inclusion and exclusion criteria for being in the study prespecified and 
applied uniformly to all participants?          
5. Was a sample size justification, power description, or variance and effect estimates provided?   
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the 
outcome(s) being measured?          
7. Was the timeframe sufficient so that one could reasonably expect to see an association 
between exposure and outcome if it existed?          
8. For exposures that can vary in amount or level, did the study examine different levels of the 
exposure as related to the outcome (e.g., categories of exposure, or exposure measured as 
continuous variable)?          
9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and 
implemented consistently across all study participants?          
10. Was the exposure(s) assessed more than once over time?          
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and 





12. Were the outcome assessors blinded to the exposure status of participants?          
13. Was loss to follow-up after baseline 20% or less?          
14. Were key potential confounding variables measured and adjusted statistically for their impact 
on the relationship between exposure(s) and outcome(s)? 
For each item, possible choices were “yes”, “no” or “other” (i.e. “cannot determine”, “not 
applicable” or “not reported”). 
 
After completion of the systematic review, several demographic, socioeconomic, clinical 
and treatment-related factors associated with QoL in ART-treated sub-Saharan HIV adult 
































The second part of this dissertation was a cross-sectional study with the aim to measure 
the QoL of HIV patients receiving long term-ART in a community health clinic in Togo (Aim 
2a), and assess the association between key risk and protective factors and QoL (Aim 2b). 
 
Study Setting 
 The study was conducted at Espoir Vie Togo (EVT), a community health clinic in Lomé, 
Togo. EVT is a non-governmental organization created in 1995 and its mission is to treat and 
provide social support to PLHIV in Togo. A team of 79 healthcare providers (physicians, 
medical assistants, nurses, midwives, etc.) at three locations in the country (Lomé [Togo’s 
capital], Aného, Sokodé) manages about 3,500 PLHIV, and this number has been steadily 
increasing over the last two decades.51 
 
Sampling Strategy 
The study’s target population was western and central African PLHIV.  
Lomé university hospital, Centre Hospitalier Universitaire (CHU) Sylvanus Olympio, refers 
patients to EVT, which accepts all referred patients without exclusion. Patients come from 
various socioeconomic backgrounds and they are representative of urban HIV patients in west 
and central Africa. 
 
Study Subjects 
 Participants were consecutive men and women HIV patients who visited the outpatient 





token as reimbursement for travel expenses (Appendix L). Eligibility criteria were as follows: 
>=18 years, a confirmed HIV diagnosis and currently taking ART. 
 
Ethical Approval 
Ethical approval was obtained from the Comité de Bioéthique pour la Recherche en Santé 
(031/2019/CBRS) in Togo (Appendix J), and from the University of Texas Health Science 
Center at Houston’s Committee for the Protection of Human Subjects (HSC-SPH-19-0357) 
(Appendix K). All participants provided verbal informed consent. 
 
Sample Size Calculation 
We estimated the sample size based on a fixed model and R-squared increase for linear 
multiple regression. We assumed a medium population effect size (i.e. 0.15; corroborated by a 
previous study conducted in China)53, a power of 80%, a significance level of 5%, and 15 
predictors. Using G*Power software Version 3.1.9.4, a sample size of 140 was generated.52 
 
Data Collection 
 Two study investigators (Oubote Sangbana [primary investigator]; Jean Marie Atsou-
Alley [secondary investigator and EVT’s clinical psychologist and patient coordinator]) collected 
data before or at the end of patients’ doctor visits. The clinic’s primary physician (Nina Dapam) 
asked patients if they were interested in participating in the study and, in case of a positive 
response, they were directed towards the study investigator. The investigator explained the 
objective of the study following a verbal script (Appendix E), then sought verbal informed 
consent. If verbal informed consent was obtained, data collection proceeded, in two phases. 
First, basic demographic and socioeconomic characteristics were collected from the patient’s 





identified during the systematic review were also collected directly by asking patients. Overall, 
the characteristics collected were: gender, age, education level, employment, marital status, body 
mass index (BMI), HIV status disclosure, social or family support, alcohol use, food insecurity, 
serostatus, CD4 count, viral load, treatment duration, ART regimen, line of treatment, adherence, 
and side effects. Second, participants were administered the French version of the MOS-HIV 
survey (Appendix G,H). Survey questions were digitalized beforehand: rather than being in a 
paper form, the questionnaire was entered on the Qualtrics application on an Apple iPad and the 
investigators read the questions to the patients and recorded the answers directly on the Qualtrics 
application. 
 
Table 2. Collectable data from EVT patients’ visit cards. 
Variables 
Page 1 Page 2 
Temperature Opportunistic Infections (Type) 
Pulse Opportunistic Infections (Treatment) 
Blood Pressure Side Effects 
Weight TB Test Requested 
Height Suspected TB (Yes, No) 
Age † Confirmed TB (Yes, No) 
Status (Well, Can Move, In Bed) Date TB Confirmed 
Pregnant TB Treatment 
CD4+ count | Date Collected Other Concomitant Diseases 
Viral Load Adherence to ART (Yes, No) ! 
ART Status (Start, Continued, Change, Stop) Number of Doses Omitted in the Last Week 
Reason for Changing ART a Hemoglobin Level * 
Reason for 2nd Line ART ALT or SGPT b 
Reason for Stopping ART Creatinine 
ART (Original 1st Line, Switched 1st Line, 2nd Line Blood Sugar 
Concomitant Medication Triglycerides 
Duration of Treatment Cholesterol 
Treated for Opportunistic Infections Amylase 
Co-trimoxazole Prophylaxis Lipase 
 CPK 
a Antiretroviral Therapy; b Alanine transaminase or serum glutamic-pyruvic transaminase; * Bolded variables indicate the latest 








The survey administered was the MOS-HIV (Appendix G,H). It is a previously validated 
instrument that produces an overall QOL profile specific to HIV patients. It assesses health 
transition and 10 dimensions of QoL: general health perceptions, pain, physical functioning, role 
functioning, social functioning, energy/fatigue, mental health, health distress, cognitive 










Figure 1. Dimensions of the MOS-HIV health survey. 
 
The MOS-HIV is a disease-specific instrument and contains 35 items. Items are scaled on 
a 3, 5 and 6-point Likert scale without weighting of items. After linear transformation, the scores 
range from 0 to 100, where higher scores indicate better QOL. Guidelines for calculating the 
scores for each dimension are provided with the survey upon request.  
The French version of the MOS-HIV and permission to use the questionnaire were obtained by 
submitting a request on the dedicated website supported by Mapi Research Trust.56 
Pain 
























Aim 2a: MOS-HIV Scores 
Per scoring guidelines, 11 of the 35 items were recoded to reverse their directionality. 
Items composing each scale were summed up to compute raw scores, as shown in Table 3. Raw 
scores were transformed linearly to a 0-100 scale according to the following formula: 
[(maxnew – minnew) / (maxold – minold)] x [(v – maxold) + maxnew] 
where maxnew and minnew are 0 and 100, respectively, minold and minold are the item’s minimum 
and maximum boundaries, and v is the observed value.  
Then, a physical health summary (PHS) score and a mental health summary (MHS) score were 
computed using a factor analysis with oblique rotation, as described by Revicki (1998).57 All 
coding and computation were performed using SAS software, Version 9.4, SAS Institute Inc.59 
 
Table 3. Equations to compute MOS-HIV dimensions scores. 
Domain Equation* 
General health perceptions Q1 + Q11a + Q11b + Q11c + Q11d 
Physical functioning Q4a + Q4b + Q4c + Q4d + Q4e + Q4f 
Role functioning Q5 + Q6 
Social functioning Q7 
Cognitive functioning Q10a + Q10b + Q10c + Q10d 
Pain Q2 + Q3 
Mental health Q8a + Q8b + Q8c + Q8d + Q8e 
Energy/Fatigue Q9a + Q9b + Q9c + Q9d 
Health distress Q9e + Q9f + Q9g + Q9h 
Quality of life Q12 
Health transition Q13 






Aim 2b: Multiple Linear Regression 
Two multiple linear regression analyses, one with PHS as the dependent variable, and the 
other with MHS as the dependent variable, were fitted to determine the factors associated with 
QoL. The independent variables were gender, age, education level, employment, marital status, 
BMI, HIV status disclosure, social or family support, alcohol use, food insecurity, serostatus, 
viral load, treatment duration, ART regimen, line of treatment, adherence, self-evaluated health 
status and side effects. All analyses were performed using SAS software Version 9.4.59 
Data Preparation. After data cleaning, independent variables were inspected for 
multicollinearity using correlation matrices. In case of highly correlated variables, one variable 
was dropped. 
Preliminary Models. For each health summary score (PHS and MHS), a preliminary model was 
fitted using the domain score (continuous) as the dependent variable and risk or protective 
factors (continuous, binary or categorical) as the independent variables. 
Diagnostics. All linear regression assumptions were assessed, and remedial measures such as 
variable transformation were applied in case of assumptions’ violations.  
Model Selection. Stepwise model selection was performed to determine the subset of variables 
best defining the relationship between the independent variables and the specific health summary 
score under investigation. 
Model Validation. The most parsimonious model selected during the model selection phase was 
validated using the data splitting approach (or cross-validation). The dataset was randomly split 
into two equal sets. One set was used as the model-building (training) set. The other set was used 





estimates in the validation set, and the agreement between estimated β coefficients and standard 
errors between the two sets was assessed. 
Potential influential points were then analyzed in the model-building set. 
 
Results from the model selection were reported in a table showing the dependent variable 
(PHS and MHS), the independent variables selected during model selection, the β coefficients, 
the 95% confidence intervals and the p-values. The directionality of variables statistically 







The third part of this dissertation was a qualitative assessment of ART-treated HIV 
patients with the aim to understand patients’ definitions of QoL, identify and gain additional 
knowledge on underlying and undiscovered indicators of quality of life, and better understand 
the life experiences of HIV patients in this population. 
 
Data Collection 
 Every day, one patient visiting the outpatient clinic was asked to participate in the 
qualitative assessment, in addition to being administered the MOS-HIV survey, before or after 
the doctor visit. Face-to-face individual interviews took place before administering the survey to 
ensure participants’ responses were not limited by the constructs and dimensions used in the 
survey. Participants were given a 500 CFA (~ US $0.85) token as reimbursement for travel 
expenses (Appendix L). Eligibility criteria to be interviewed for the qualitative assessment were 
being 18 years or older, having a confirmed HIV diagnosis and currently taking ART more than 
six months.  
The primary investigator (OS), assisted by a clinical psychologist with qualitative 
interview experience (JMAE), conducted the interviews, which were held in a private 
consultation room to ensure patient’s confidentiality. All interviews were held in French, the 
official language and first language of most participants. No time limit was predetermined but 
the interviews lasted approximately 15 minutes. The interview was recorded on a digital audio 
recorder, and written notes were also taken by the study investigator during the discussion. No 





participants to engage in a conversation rather than a question-answer session. This approach 
also encouraged participants to give honest answers.  
Based on an interview guide specifically developed for this study, a series of open-ended 
questions were asked: 
1. a) What is a good quality of life for you?  
b) How is that different or similar to what others experience? 
2. a) How have your ideas of a good quality of life changed after HIV? 
b) What was it before and how has that changed over time and in relation to what? 
3. Are there things or people that put your quality of life at risk? Please tell me about them. 
The questions were open-ended, and the investigator discussed risk and protective factors 
more in depth as deemed necessary. The overall aim was for participants to share their definition 
of QoL and describe the factors improving or impeding their quality of life in the context of HIV. 
 
Ethical Approval 
Ethical approval was obtained from the Comité de Bioéthique pour la Recherche en Santé 
(031/2019/CBRS) in Togo (Appendix J), and from the University of Texas Health Science 
Center at Houston’s Committee for the Protection of Human Subjects (HSC-SPH-19-0357) 
(Appendix K). All participants provided verbal informed consent. 
 
Data Analysis 
 Audio recordings were fully transcribed and translated from French to English. Hand-
written notes were typed and translated in English. Data analysis was performed using 
OpenCode version 4.0.60 Data were analyzed following a thematic analysis. Transcripts were 





open coding approach to capture the participants’ life experience and perception of QoL. After 
coding several transcripts, a set of codes were defined and subsequently used for similar 
recurring concepts. Additional codes were incorporated into the analytical framework as they 
were identified in subsequent transcripts. Several themes emerged and were examined at the 
latent level: the investigator sought to detect underlying ideas and concepts by analyzing 
patients’ words beyond what was said verbatim during the interviews. All themes were reviewed 







Human Subjects, Animal Subjects, or Safety Considerations  
 
This dissertation included the use of the MOS-HIV, a previously validated questionnaire, 
for the assessment of QoL in human subjects. The latter consisted of HIV patients treated at 
Espoir Vie Togo, a community clinic in Lomé, Togo. Data collection took place during a one-
month period and involved 147 patients. Each patient was assessed only once, and the survey 
was completed in approximately 10 minutes. Participants were given a 500 CFA (~ US $0.85) 
token as reimbursement for travel expenses. Verbal informed consent was sought to access 
patients’ medical records in order to collect demographic data and the most recent clinical data 
prior to the assessment. Patients were clearly informed of their right to not participate in the 
study and of their ability to withdraw from the study at any time if they chose to do so. Proper 
ethical approvals were requested from UTHealth’s Committee for the Protection of Human 
Subjects (CPHS) and the Togolese Comité de Bioéthique pour la Recherche en Santé. A letter of 
support was obtained from Espoir Vie Togo since it does not have an ethics committee 
(Appendix I). 
The main risks incurred by study participants were breach of confidentiality and loss of 
privacy since the investigators (Oubote Sangbana [primary investigator]; Jean Marie Atsou-Alley 
[secondary investigator and EVT’s clinical psychologist and patient coordinator]) accessed 
private information included in patients’ medical records. This risk was mitigated by accessing 
the record in front of the patient, only for a brief period and only to record the few demographic 
and clinical variables necessary for the completion of the study. No personal identifying 
information was collected. Moreover, the primary investigator completed Collaborative 
Institutional Training Initiative (CITI) training for the protection of human subjects and ethical 





investigator, who is in contact daily with the clinic’s patients, was previously trained on-site by 
local administrators to maintain patient privacy and protect human subjects. 
The Apple iPad used for the questionnaire assessment was password-protected and only the two 
study investigators knew the password. It was not connected to the internet. All data collected on 
the iPad were deleted once transferred to the primary investigator’s password-protected laptop 
computer for analysis. 
In summary, the benefits of the findings of this study exceeded the risk incurred, and the 































JOURNAL ARTICLE 1 
 
Drivers of Quality of Life in HIV Patients Treated with Antiretroviral Therapy in Sub-
Saharan Africa: A Systematic Review. 
 





























As HIV evolved from a fatal infection to a chronic disease, quality of life (QoL) has 
emerged as a significant medical outcome. The objective of this systematic literature review was 
to identify key risk or protective factors associated with QoL in sub-Saharan Africa. We 
searched Medline, PubMed, Embase, and PsycINFO from inception to May 2019 and GreyNet 
and International AIDS Conference archives for original publications. Two screeners 
independently reviewed titles and abstracts, and full texts of relevant articles for factors 
statistically associated with QoL. In all, 41 observational studies with multivariate analyses 
conducted in 14 countries met eligibility criteria. As reported in 9 or more studies, higher QoL 
was associated with sociodemographic factors: younger age, employment, higher education 
level, male gender, and social or family support; and a treatment-related factor: longer treatment 
duration. Lower QoL was associated with clinical factors: mental health and lower CD4 count. 
This review summarizes the evidence in the literature and highlights key factors affecting the 






In the last decade, the scale-up of antiretroviral therapy (ART) has changed the course of 
the HIV/AIDS epidemic in sub-Saharan Africa, with an estimated 40% reduction in HIV-related 
mortality from 2010 to 2018 (1). Although there were an estimated 470,000 HIV-related deaths 
in 2018, HIV has shifted from a fatal disease to a chronic condition and the HIV care continuum 
and management approach have evolved to meet the demands of this new paradigm (2). As a 
result, quality of life (QoL) has emerged as a significant outcome during follow-up for those 
receiving ART (3,4). Measuring QoL is key to documenting the burden of disease, monitoring 
changes in health, evaluating the efficacy of ART, and analyzing the cost-effectiveness of ART 
programs (5). Moreover, patients who maintain a good QoL as they cope with their disease are 
more likely to adhere to treatment and thus reduce virologic failure and drug resistance (6,7). It is 
therefore crucial to determine the main factors associated with QoL to ensure healthcare 
providers use the most relevant, up-to-date evidence in implementing interventions that help 
patients to effectively stay in care and remain asymptomatic. 
An increased research interest in the determinants of QoL has been observed in low-income 
countries in the last decade, and yet, a synthesis of recent findings on the topic has to be 
published. This gap is especially important for sub-Saharan Africa, where the course of the 
disease is unique due to its historical, religious, and cultural singularities. The profile of the 
epidemic also differs from other regions because of the diverse distribution and prevalence of 
HIV subtypes across countries in sub-Saharan Africa (8,9,10). There is a need for a region-
specific review to capture this part of the African experience and provide a comprehensive 





objective of this review was to identify and summarize the factors associated with QoL among 
sub-Saharan adult HIV patients treated with antiretroviral therapy. 
 
Methods 
This systematic review was conducted following Methodological Expectations for 
Cochrane Intervention Reviews (MECIR) standards and reported according to Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (11,12). The 
protocol was registered with the international prospective register of systematic reviews 
(PROSPERO CRD42019136202) and can be accessed on PROSPERO’s website. 
 
Inclusion criteria 
Inclusion criteria followed a pre-specified PICOTS framework (13). The population was 
HIV patients aged 18 years or older under treatment with ART or highly active antiretroviral 
therapy (HAART) for any duration; independent variables were any sociodemographic, clinical, 
behavioral or treatment-related variables, the outcome of interest was any quality of life 
assessment obtained using a standardized questionnaire or instrument (e.g. World Health 
Organization Quality of Life-HIV [WHOQOL-HIV], Medical Outcomes Study HIV Health 
Survey [MOS-HIV], EuroQol-5D [EQ-5D]). Any publication date was accepted, the setting was 
a sub-Saharan country, and all quantitative study designs were considered. In addition, studies 
had to include an adjusted analysis assessing an association between QoL and risk or protective 
factors. There were no language restrictions. 
 
Search strategy 
We searched Medline, PubMed, Embase, and PsycINFO from inception to May 2019 to 





database sources including GreyNet and the international AIDS conference archives were 
searched for abstracts, presentations and unpublished articles. The following concepts were 
tailored for each database: HIV/AIDS, ART, quality of life and sub-Saharan Africa. The search 
query for Medline is available in the supplementary material (Supplementary Table 1), and 
others from HS. All citations found through searches were stored on RefWorks (ProQuest, 
Michigan, USA). Search results were tracked and managed using an Excel workbook designed 
for this purpose (14). 
 
Study Selection 
Two authors (HS, PE) independently screened all titles/abstracts. Prior to screening, the 
authors reviewed a random sample of 76 titles/abstracts to assess interrater reliability (Cohen's 
kappa [standard error] = 0.86 [0.076]) (15). Disagreements were resolved by consensus. 
Subsequently, full texts of relevant studies were reviewed independently (HS, AL) and 
disagreements were also resolved by consensus. 
 
Data collection 
One reviewer (HS) used a standardized data collection form to extract the following data 
items from each included study: author’s name, publication year, country, study design and 
duration, sample size, population characteristics, ART regimen, QoL instrument, and risk or 
protective factors whose association with improved or reduced QoL was investigated through an 
adjusted statistical analysis. We collected all statistically significantly associated (p<0.05) 








Risk of bias assessment 
One reviewer (HS) assessed the likelihood of bias in each included article using National 
Institutes of Health’s 14-item quality assessment tool for observational cohort and cross-
sectional studies (16). For each item, possible choices were “yes”, “no” or “other” (i.e. “cannot 
determine”, “not applicable” or “not reported”). According to the tool, studies were categorized 
as “good”, “fair” or “poor”, and a second reviewer (AL) reviewed all ratings. Disagreements 
were resolved by consensus. 
 
Results 
From all sources, 795 unduplicated records were identified, and 41 studies met inclusion 
criteria (Figure 1). Main reasons for exclusion were: ART was not the intervention of interest, 
risk factors were not investigated, and analyses were not adjusted. 
 
Description of studies 
Included studies were published from 2007 to 2019 and conducted in 14 sub-Saharan 
African countries. Ethiopia (k= 10), Uganda (k= 7), Nigeria (k= 5) and South Africa (k= 5) were 
the most frequent countries of research. All studies were observational, including 27 (66%) 
cross-sectional surveys. The total sample size was 18,055. Ten different QoL instruments were 
used, including WHOQOL, MOS-HIV, 36-Item Short Form Survey (SF-36), EQ-5D, and the 
HIV/AIDS-Targeted Quality of Life Instrument (HAT-QoL). Moreover, nine studies reported 
associations with QoL as an overall score while 32 studies assessed associations with specific 
domains of QoL. Study characteristics and main findings are shown in the supplementary 




















































(k = 699) 
 
Full-text articles excluded 
(n = 55) 
3 No std. QoL instrument 
8 No risk factors 
1 Wrong population 
1 Not in sub-Saharan Africa 
20 Wrong intervention 
10 No adjusted analysis 
4 Secondary analyses 
1 FT unavailable 
7 Other 
Records identified through 
database searching 
(k = 1567) 
Additional records identified 
through grey literature 
(k = 3) 
Records after duplicates removed 
(k = 795) 
Records screened 
(k = 795) 
Full-text articles assessed 
for eligibility 
(k = 96) 
Studies included in 
qualitative synthesis 





Quality of individual studies 
Twenty-seven studies demonstrated an overall strong internal validity and were rated as 
good. These studies were conducted based on a robust methodology, and no significant flaws in 
the conduct of the study or the statistical analyses were identified. Twelve studies were rated as 
fair, as they presented one or several weaknesses increasing the risk of bias such as the method 
of selection of participants or confounding. Lastly, six studies overall were rated as poor because 
of a high risk of bias, notably in the statistical analyses or in the methodology related to the 
measure of the risk factors or the measurement of QoL. 
 
Heterogeneity across studies 
When assessing heterogeneity across studies, we found several differences in the 
methods. Ten different instruments were used across studies to measure QoL and this diversity 
may impact the overall joint evidence since QoL domains vary across instruments. For example, 
MOS-HIV is always summarized into two domains (physical and mental health summaries) for 
analyses purposes, while WHOQOL-HIV is more comprehensive and measures six domains 
(physical, psychological, level of independence, social relationships, environment, 
spirituality/religion/personal beliefs). Lastly, both generic and disease-specific instruments were 
used across studies. On one hand, generic instruments assess QoL changes resulting from overall 
clinical features and they are designed for use across different patient populations. On the other 
hand, disease-specific instruments are generally more sensitive and better designed to measure 








Table 4. Factors associated with quality of life identified in 41 studies. 
Characteristic 
Number of studies reporting an 




Education Level 10 
Gender 10 
Social/Family Support 9 
Marital Status 7 
Region/Residence (Urban/Rural)/Type of clinic 6 
Food security/Diet diversity 6 
Knowledge of partner's HIV status/Disclosure of status 4 
High risk sexual behavior/Sexual activity/Number of 
partners 
4 






CD4 Count 9 
WHO Stage 7 
Symptoms 5 
Health Status/Illness (self-evaluated)/Hospitalization 4 
Baseline QoL/Domain of QoL 4 
Tuberculosis 3 
Viral Load/Plasma HIV copies 3 
NCD/Chronic disease/Comorbidity 3 
Treatment-Related Factors 
Treatment Duration/Follow up time 11 
ART/Type of regimen 4 
Adherence 4 
Side Effects/Toxicity 3 
*Overall quality of life or domains of quality of life. 
All associations statistically significant at p<0.05. 
SES: socioeconomic status, BMI: body mass index, PTSD: post-traumatic stress disorder, NCD: non-communicable disease, 
ART: antiretroviral therapy, QoL: quality of life. 
 
 
Factors associated with QoL 
Factors associated with QoL were grouped into three categories: sociodemographic, 
clinical and therapy-related factors. Only one study did not find any statistically significant 





statistically significant associations between QoL and risk or protective factors, after adjustment. 
A summary of these factors and their positive or negative impact on QoL is found in table 2. 
 
Sociodemographic factors 
Age was the most frequently reported factor: most studies found that older age was 
associated with poorer QoL (27,28,35), especially the physical domain (19,33,41,45,49). Level 
of education was also frequently reported. Specifically, QoL was higher when patients were 
literate or educated (23,26,44), and when patients had reached a secondary level of education or 
higher (18,33,41). Being employed or having a regular or high source of income were associated 
with higher QoL (28,34,37), specifically the physical, mental, psychological, and social domains 
(19,23,24,27,41). Women experienced poorer QoL in the physical, mental, and social 
relationships domains (19,32,39,56). Regarding marital status, higher scores were measured in 
married patients or patients cohabiting with or having a stable partner (21,33,35). Similarly, 
receiving social or family support was associated with higher QoL scores (23,24,33,34,41,44,51). 
Residing in a rural area was associated with poor QoL (18,23,34). There was a consensus that 
food security increased QoL scores (39,41,57). Also, malnutrition (24,33) and poor diet diversity 
(22) were associated with lower scores. Findings for the association between body mass index 
and QoL were inconsistent based on the three studies investigating this factor. Patients with 
abdominal obesity (21) or underweight (23) had poorer physical scores whereas being 
overweight increased mental scores (41). Knowledge of the partner's HIV status or disclosure of 
one’s own status were associated with better QoL (18,21,32). Stigma negatively affected 
psychological and mental domains of QoL (33,34,57), and so did a high-risk sexual behavior 







A higher CD4 count (54), more specifically, a count above 200 cells/mm3 (32,42,46,50), 
or 350 cells/mm3 (21) was associated with higher QoL scores. Mental health factors such as 
depressive disorders (29,40,52,54,57) psychological distress (28), mental disorder (37) or post-
traumatic stress disorder (53) were associated with lower QoL scores. Patients with less severe 
WHO clinical staging scored higher in most QoL domains (25,32,42), but mainly in the physical 
domain (33,54). Poorer physical scores were measured in symptomatic patients (19,57). 
Tuberculosis (TB) co-infection was found to have a negative association with physical (23,32) 
and psychological (33) scores. Several studies reported the association of higher viral load with 
lower QoL (48,54). An increase in physical and mental health summary scores at follow-up was 
measured in patients who had lower baseline QoL scores (45,49). 
 
Therapy-related factors 
The effect of treatment duration or follow up time on quality of life was extensively 
studied. All eleven studies measuring this association reported that longer treatment duration or 
follow up time was associated with higher QoL scores. Moreover, being on ART was associated 
with higher QoL scores (18,35,47), while treatment-related side effects or toxicity was 
negatively associated with both physical and mental domains of QoL (34,41,48,49). 









Factors associated with QoL in studies of “good” quality 
We stratified our results according to our assessment of the quality of individual studies 
(Supplementary Table 2). When evaluating factors associated with QoL in studies rated as 
“good”, we found that being on ART and being employed were most frequently reported. Age, 
gender and depression were also found to be main factors associated with overall or domains of 
QoL. A comparison of our findings in prospective cohorts with those in cross-sectional studies 
did not indicate any marked trends. However, more factors, especially sociodemographic, were 
investigated in cross-sectional studies. Reasons for this trend were unclear but it is possible that 
longitudinal studies focused on detecting changes or developments in specific variables of 
interest, which would make analyses of other factors less meaningful. 
 
 
Table 5. Risk and protective factors associated with higher or lower quality of life. 
Factors associated with higher QoL Factors associated with lower QoL 
Higher education Older age 
Being employed/higher SES Being a woman 
Being married/cohabiting Residing in a rural area 
Receiving social or family support Food insecurity/malnutrition/poor diet diversity 
Being treated in an NGO Stigma 
Knowing partner's HIV status/disclosing own status High-risk sexual behavior/high number of partners 
Higher CD4 count 
Depression/psychological distress/mental 
disorder/PTSD 
Lower WHO clinical stage Tuberculosis 
Higher baseline QoL scores Higher viral load 
Longer treatment duration or follow up time Treatment-related side effects or toxicity 
Receiving ART  
Adhering to ART  










We conducted a systematic review to identify and compile the factors associated with 
QoL among ART-treated HIV patients in sub-Saharan Africa to address the lack of 
comprehensive overview on this issue. Our review uncovered multiple factors associated with 
QoL and we categorized them into three groups: sociodemographic factors, which included age, 
education, socioeconomic status, gender, marital status and social or family support; clinical 
factors, which included CD4 count and mental disorder; and treatment-related factors, which 
included treatment duration and ART treatment. Our findings were based on data from 41 studies 
carried out in 14 countries, including countries where the number of PLHIV is the highest in the 
region (i.e. South Africa, Nigeria, Kenya, and Tanzania). The populations included in our review 
came from various backgrounds and settings. We were able to gather evidence from primarily 
high-quality studies, and overall, the results presented in our review are reflective of the current 
literature on the topic.  
Sociodemographic risk factors were found to influence QoL more frequently than clinical 
or treatment-related factors. This was unsurprising considering that it is simple and inexpensive 
to collect patients’ characteristics and it does not require any special equipment or laboratory 
analyses. As a result, more sociodemographic risk factors were included in our analyses and this 
may explain why 12 sociodemographic factors were associated with QoL in three or more 
studies in our review, compared with nine studies for clinical factors and only four for treatment-
related factors. Our findings are consistent with results from prior research, notably Degroote’s 
(2014) review of the determinants of QoL among PLHIV in high-income countries (59). This 
review of the literature included 49 studies mainly conducted in the North America and 





as gender, age, family situation, or employment similarly outnumbered clinical, psychological or 
behavioral determinants of QoL, even though the authors used more subcategories to summarize 
the determinants of QoL.  
We found both similarities and differences between Degroote’s findings in high-incomes 
countries and our own results in sub-Saharan Africa. Similarities were that several factors such 
as ART, depression, stigma or social support have been extensively studied in the literature and 
they were expected to influence QoL in low- and high-income settings alike. In fact, these 
factors directly or indirectly influence health outcomes, regardless of the population affected, as 
reported in Degroote (2014) and confirmed in our review.  
The main difference between Degroote’s review and ours was that certain determinants 
of QoL were only relevant in high-income countries, while others only had a significant impact 
in sub-Saharan Africa. For example, anxiety disorders were associated with lower physical and 
mental health in high-income countries, but this association was not investigated in any of the 43 
studies in our review since screening for anxiety and certain mental health disorders are less 
common in low-income countries, and those disorders only account for a small fraction of the 
total burden of illness. Another example is healthy nutrition, which was a determinant of QoL in 
high-income countries, but not investigated in the studies in our review. In contrast, TB is a 
common comorbidity among PLHIV in sub-Saharan Africa and it was found to be negatively 
associated with QoL in three studies in our review. TB was not evaluated in any of the studies 
included in Degroote’s review, as it is not a health priority in high-income countries, even in 
PLHIV. 
Our results also complement findings from a previous systematic review assessing 





two studies conducted in sub-Saharan Africa in that review (South Africa and Uganda), ART 
increased PHS and MHS domains of QoL over 1 year, with the greatest increase occurring at 12 
and 16 weeks, respectively. Of the 15 studies included in our review that found an association 
between ART or duration of ART and QoL, seven were prospective cohorts. In all cohort studies 
but one, treatment duration or follow up time (which is a proxy for treatment duration) were at 
least six months, and a statistically significant association was found between treatment/follow 
up duration and overall (22), physical (32,39,57) and mental (31) domains of QoL. This confirms 
that ART is one of the most significant factors affecting QoL over time and its immediate start 
after diagnosis remains one of the most reliable ways to improve patients’ QoL.  
Our systematic review had several strengths. First, our focus on the sub-Saharan 
experience provides essential data that have not been summarized before in this region despite 
the severity of the epidemic and the high prevalence and incidence rates. As shown in our 
review, numerous studies assessing the QoL of ART-treated HIV patients were conducted in 
sub-Saharan Africa in the last five years and a summary of their findings was overdue to inform 
stakeholders and provide relevant evidence to guide decision making. Second, we identified and 
reported risk factors associated with QoL that were not previously described. Specifically, 
characteristics pertinent to low-income countries such as food insecurity or TB emerged as 
factors influencing QoL. 
Our review also had limitations. First, multiple instruments were used to measure QoL, 
and although all were standardized and previously validated, their diversity implies a certain 
heterogeneity when combining results across studies. Some measures provided by instruments 
such as MOS-HIV are summarized into physical and mental domains of QoL, while other 





Infection [FAHI] or SF-36). However, the impact of this heterogeneity is limited since this 
review did not specifically seek to assess how individual domains of QoL were influenced by 
various factors. Second, we included studies published from 2007 to 2019 and during this long 
timespan, access to ART considerably increased in sub-Saharan Africa. It is likely that the 
factors reported by PLHIV in the late 2000s vary from those reported in the late 2010s because 
of the difference in the availability of treatment during those two periods (61). Finally, sample 
sizes varied across studies and it is likely that chances of detecting statistically significant 
associations between certain factors and QoL were increased with larger sample sizes. Further 
exploration is warranted to assess how this issue affect our findings. 
 
Conclusion 
The QoL of ART-treated PLHIV in sub-Saharan Africa is mainly driven by 
sociodemographic, clinical and treatment-related risk factors similar to those affecting the QoL 
of PLHIV in the rest of the world. Yet, risk factors still rampant in poor- and middle-income 
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Supplementary Table 1. Search terms for Medline (May 7, 2019). 
 Search Term 
Number 
of Hits 
1 HIV-1/ or HIV-2/ or HIV/ or HIV Seropositivity/ 
665 
2 hiv infections/ or acquired immunodeficiency syndrome/ 
3 (hiv or aids).ti,ab,kw. 
4 1 or 2 or 3 
5 "Quality of Life"/ 
6 
("Quality of Life" or QOL or HRQoL or "Health-related quality of 
life").ti,ab,kw. 
7 5 or 6 
8 
africa/ or "africa south of the sahara"/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic 
of the congo"/ or equatorial guinea/ or gabon/ or africa, eastern/ or 
burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or 
somalia/ or south sudan/ or sudan/ or tanzania/ or uganda/ or africa, 
southern/ or angola/ or botswana/ or lesotho/ or malawi/ or 
mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ 
or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or 
liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra 
leone/ or togo/ 
9 
(Angola or benin or botswana or burkina faso or burundi or cameroon 
or cape verde or "central african republic" or chad or congo or "cote 
d'ivoire" or djibouti or eritrea or ethiopia or gabon or gambia or ghana 
or guinea or kenya or lesotho or liberia or malawi or mali or 
mauritania or mozambique or namibia or niger or nigeria or rwanda or 
senegal or "sierra leone" or somalia or saharan or sudan or swaziland 
or tanzania or togo or uganda or zambia or Zimbabwe).ti,ab,kw. 
10 8 or 9 










Follow-up time or 












Factors associated with overall or domains of QoL 




6 mos. follow up 
N=152 






















60% married. 82% 







PHS: Lower education level, probable depression 
and higher WHO stage (lower).  
MHS: Female gender (lower). Study visit (6 mos.) 
(higher)  
GPGI: Alcohol consumption, lower education level, 




6 mos. follow up 
N=455 




88.6% employed. 𝑥 CD4 









Common mental disorder (moderate to very high) 
(lower physical and mental QoL). No source of 













43.6% married. 30.3% 
unemployed. Median CD4 











PHS: Severe food insecurity, increasing age, female 
gender, being married (lower). Increased duration 




24 mos. follow up 
N=268 





100% CD4 < 200 cells/μL 
and/or WHO stage IV. 




in the Free State 
Province 
EQ-5D 
After 12 mos. of ART: physical and emotional QoL: 
CD4 count, viral load, treatment outcome (higher). 
Adverse effects (lower). Physical QoL: emotional 
QoL (higher). 
After 24 mos. of ART: physical and emotional QoL: 
CD4 count, viral load, treatment outcome (higher). 
Physical QoL: emotional QoL (higher)  
Stangl, 2007 
Uganda 
12 mos. follow up 
N=947 





35.2% married or 
cohabiting. 53.5% primary 





PHS: increased time on HAART, higher CD4 cell 
count, and religion (Protestant) (higher).  





124.1 cells/μl depression scores, WHO stage III-IV (lower). 
MHS: increased time on HAART, higher CD4 cell 
count, and religion (Protestant) (higher). Source of 
income (being dependent), higher depression scores 
and increased plasma HIV-1 copies (lower). 










51.7% living in couple. 
17.6% no formal education. 
71.7% CD4 count >350 
cells/mm3. 
Multicenter. 




Education level (secondary and higher), health 
region (Kara), ART, knowledge of partner’s HIV 














52.6% married. 46.7% 






PHS: regular source of income, zidovudine-based 
regimen (higher). Having symptoms, female gender, 
age above 40 y, inability to cope with HIV, 
lopinavir/ritonavir-based regimen (lower) 
MHS: Inability to cope with HIV, presence of any 












56% married. No more than 


















63.9% married. 59.9% 
primary education level. 







PHS: currently married (higher). CD4 counts <350 
cells/μL, abdominal obesity, physically inactive or 
hypertensive (lower). 
MHS: currently married (higher). Did not disclose 












74.1% males / 62.2% 
females married. 92.0% 
males / 77.2% females 
employed.  
Public health 




In both genders: education (illiterate) (I, SR, E), 
occupation (unemployed) (P,PSY, SR, E), 
undernutrition (BMI < 18.5 kg/m2) (male: P, I, E; 
female: P, PSY, I, E), depression (all domains), 
tuberculosis (male: all domains except E and SRPB; 
female: all domains except SRPB), anemia (male: P, 
PSY, E; female: P, PSY, I, E) and no family support 
(male: PSY, SR, SRPB; female: P, PSY, SR, SRPB) 
(lower). 
In females: rural residence (male: PSY, SR, SRPB; 









42.8% married. 35.5% 





Gender (PSY, SRPB), age (PSY), residence (I), 





54.7% women CD4 count ≥500 cells/mm3. Referral Hospital (Amharic 
version) 











17.5% married. 45% 
employed. 77.7% CD4 
count ≥350 cells/mm3. 
98.2% full viral 
suppression. 





Older age (I, SR, E, SRPB), being married (P, SR), 
being unemployed (P, PSY, E, SRPB), poor health 
status (all domains), coping with life by contacting a 
person with ART (S), no self-education on HIV (all 
domains), missing ≥1 appointment (P, I, SR), 
missing ART ≥1 time in the last 2 days (PSY, E), 
not understanding circumcision prevents HIV (all 
domains except PSY), not being aware of the 
multiple concurrent partnership program (P, PSY, 
I), having sex with ≥1 partner (P, PSY, SRPB), not 
discussing condom with the sex partner or not 
having a partner (SR) (lower). 












44.6% married. 40.6% 
secondary education level. 




















Mean 26 mos. 
52.1% married or 
cohabiting. 50.3% work full 








Male gender (SR), secondary/or tertiary education 
(E), being married or cohabiting (SR), a 
government health center facility (SR), social 
support (SR, SRPB), obtaining sufficient food with 
nutritional value (all domains except SRPB), having 
the opportunity to find or maintain a job (all 
domains except SR), the possibility to share 
common resources with other people (PSY, E) 
(higher). 
Increased age (P, SR, I), TB (PSY), being bed 
ridden (P, SRPB, I), WHO clinical stage IV (P, SR), 
depressive symptoms (all domains), stigma (all 
domains except P), worrying about the 
consequences of HIV disclosure (SRPB), worrying 
about taking care of family when passed away (P, 











Mean 44 mos. 
32% women, 59% men 
married. 71.2% women, 
95.1% men employed. 
Median CD4 cell counts: 








No psychosocial support outside family (women: P, 
SR; men: P), WHO stage I-III (women: SRPB), 
illiteracy (women and men: P, SR), rural residence 
(women: PSY, I, E), no psychosocial support from 





men: 296 cells/mm3. stigma (women: PSY; men: all domains except SR 
and E), younger age (women: SR), family size <=2 
(women: SRPB; men: E), recent side effect (women: 
I), non-adherence (men: E, SRPB), being 
unmarried (men: SR) (lower).  
≥ average monthly income (women: P, SR, E; men: 
I, SR), <36 mos. on ART (women: P, SR), <36 mos. 
since diagnosis (women: E), lower WHO stage 
















Aggregated PCS and MCS: age, gender, religion, 
occupation, clinical symptoms, chronic illnesses, 





























22.6% married. 𝑥 CD4 











PCS: Increasing age, financial difficulties paying for 
HIV biological monitoring in the previous 3 mos., 
living below the poverty line, BMI <= 18.5 kg/m2, 
CD4 count <100 cells/μl, hospitalization during the 
previous 6 mos., experience of AIDS-defining 
events, side-effects during the previous 4 weeks 
(lower). Female gender, university educational level 
(higher). 
MCS: Semi-urban area of residence, financial 
difficulties paying for HIV biological monitoring in 
the previous 3 mos., living below the poverty line, 
side-effects during the previous 4 weeks (lower). 
Increasing age, being a homeowner, always having 
at least two meals per day, BMI >25 kg/m2 and 









48.3% married. 87.4% 
employed. 48% CD4 count 





WHO stage III-IV (V, MH) (lower). AIDS (CD4 


















Duration of treatment >12 mos. (RP, RE), CD4 cell 
count >200 cells/mm3 (BP, VT, RE), adherence to 
doses of HAART (PHS), and adherence to schedules 









35.4% married. 39.6% 
unemployed. 𝑥 CD4 count 
Chitungwiza 
Regional Hospital 

































43.6% married. 20.3% CD4 






PHS: CD4 count ≥200 cells/mm3, informational 
social support (higher). 










69.9% did not work for 
pay. 𝑥 CD4 count 276.9 
cells/mm3. 
Six HIV clinics 
MOS-SF-
12 











40.6% married. 46.9% 
employed. 𝑥 CD4 count 
358 cells/μl. 






Younger age (SRPB), being asymptomatic (SRPB) 
(higher). 




6 mos. follow up 
N=439 





















No source of income (PSY, SR, I, E), no social 
support (all domains except SRPB), severe acute 












44% married. 41.5% 
employed. Median CD4 











Follow up time (PSY, P), male gender (P, overall), 
disclosure of HIV status (PSY, SR), CD4 count 
≥200 cells/mm3 (P, I, SR, E, overall), WHO stage 
III-IV (all domains except P and E), good baseline 
QoL (all domains) (higher). 




median 2.1 yrs. 
follow up 
N=422 





44% married. 85% primary 
education or more. CD4 





PHS: Increased age, increased symptom index score, 
depression, food insecurity, internalized and enacted 
stigma (lower). Increased follow up time (higher). 
MHS: Increased symptom index score, depression, 
unemployment, food insecurity, internalized and 














42% married. 65% 
employed. Median CD4 








PHS: Lower baseline PHS scores, younger age 
(higher).  






~12 mos. (CBART) 
program. 











57.4% married. 58.7% at 





















65% men, 46% women 
married. 72% less than 
secondary education levels. 
Starting ART 






Psychological distress (mild, high), unemployment, 
late ART initiation, being a man between the ages of 
30–39 yrs. (vs. <=29), being a man reporting the last 
sexual encounter occurring in the previous 3 mos. to 




















𝑥 35.5 yrs. 
64% women 
ART 
Mean 4 mos. 
34.3% married. 42% 
employed. 






Physical function: Fewer comorbid medical 










Mean 29 mos. 
23% married. 41.4% low 
socioeconomic status. 




Depressive disorder (all domains except SR), 
gender (SR), and presence of medical problems (P, 
PSY) (lower). 
Highest educational level (all domains except SR), 
perceived level of social support (P, SR, overall), 
number of dependent (P), age (PSY, overall), 















PTSD (PF, MF, RF, SF, HP), number of negative life 
events (PF, MF), age (PF), number of symptoms 
(PF), risky sexual practices (P) 













50.4% currently in 
relationship. 60.9% ever 
attended school. 
LSTART. Six 
HIV clinics in the 
Oromia region 
HAT-QoL 





maximum 9 yrs. 
follow up 
N=51 





75% married or stable 
partnership. 54.9% at least 
grades 11 or 12 of 




ART (overall, PWB, EWB, SWB), being 
married/having a stable partner (overall, PWB, 
FGWB, CF) (higher). 





488 cells/mm3. (overall, FGWB, CF), high-risk peno-vaginal sex 




6 mos. follow up 
N=102 





𝑥 CD4 count 181.5 
cells/mm3. 
16 public clinics EQ-5D 
Increased yrs. of education, emotional support, 
increased CD4 count (higher). 
Pitt, 2009 
South Africa 
48 weeks follow 
up 
N=295 














PHS: after 48 weeks, higher pre-HAART scores, 
baseline viral load <=5.0 log copies/ml, older age, 
drug toxicity (lower). 
MHS: after 48 weeks, higher pre-HAART scores 
(lower). 










54.1% married. 60.7% 
employed. 
Three HIV care 
support centers 
&QOLS No statistically significant associations found 
QoL = quality of life; HRQOL = health-related quality of life; NGO = non-governmental organization; PTSD = post-traumatic stress disorder 
**WHOQOL-HIV (Domains: Physical = P, Psychological = PSY, Level of Independence = I, Social Relationships = SR, Environment = E, Spirituality/Religion/Personal 
Beliefs = SRPB). #MOS-HIV = Medical Outcomes Study-HIV. %MOS-SF-36 = Medical Outcomes Survey Short Form 36 (Physical functioning = PF, Role limitation due 
to physical problems = RP, Role limitation due to emotional problems = RE, Vitality = V, Mental health = MH, Social functioning = SF, Bodily pain = BP, General health = 
GH, Physical component summary = PCS, Mental component summary = MCS). ##RAND SF-36 = RAND 36-Item Short Form Survey. *EQ-5D = EuroQol Five 
Dimensions Questionnaire. EQ-5D-3L = EuroQoL Five Dimensions Three-level. ̂ HAT-QOL = HIV/AIDS-Targeted Quality of Life (Overall function = OF, life 
satisfaction = LS, health worries = HW, financial worries = FW, medication worries = MW, HIV mastery = HIVM, disclosure worries = DW, provider trust = PT, sexual 
function = SF). $GPGI = Global Person Generated Index. $$FAHI = Functional Assessment of HIV Infection (Physical well-being = PWB, emotional well-being = EWB, 
functional/global well-being = FGWB, social well-being = SWB, cognitive functioning = CF). +SF-36 = 36-Item Short-Form Health Survey (Bodily pain = BP, general 
health = GH, mental health = MH, physical function = PF, limitation in role due to emotions = RE, limitation in role due to physical health = RP, social function = SF, 
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Introduction: Few studies have investigated the factors associated with the physical and 
mental domains of quality of life (QoL) among HIV patients in western and central Africa, 
and none in Lomé, Togo. The objective of this study was to assess the QoL of adult HIV 
patients of a community health clinic with a strong social support component in Lomé and 
identify factors associated with QoL in this population. 
Methods: A cross-sectional study was conducted at Espoir Vie Togo in July and August 
2019 with 147 consecutive adult HIV patients receiving long-term antiretroviral therapy. 
QoL was assessed using the medical outcome study-HIV health survey (MOS-HIV). We 
identified risk and protective factors associated with physical health summary (PHS) and 
mental health summary (MHS) scores using multiple linear regression analyses with stepwise 
model selection. 
Results: Mean (SD) PHS and MHS scores were 80.7 (13.9) and 66.7 (11.1), respectively. 
Younger age, male gender, food security, the absence of treatment-related side effects, and 
self-evaluated “excellent or very good” health status were significantly associated with 
higher PHS scores. Male gender, a higher education level, food security, family or social 
support and self-evaluated “excellent or very good” and “good” health status were 
significantly associated with higher MHS scores. 
Conclusions: Patients treated at the clinic had an overall high QoL, which was associated 
with socio-demographics risk factors also found in other studies in western and central 
Africa. Our findings suggest that community health clinics with a strong social component 






The life expectancy of HIV patients who initiate antiretroviral therapy (ART) early 
and adhere to treatment has increased substantially in the last decade [1,2]. AIDS-related 
mortality decreased by 42% from 2004 to 2017 in eastern and southern Africa, and by 24% 
in western and central Africa [3]. As a result, HIV prevalence in the WHO Africa region is 
now steadily increasing [4]. In 2018, an estimated 110,000 people were living with HIV in 
Togo, of which 72,745 (66.1%) were registered in healthcare facilities, and 64,842 (59%) 
were receiving life-saving ART [5]. Because of the shift of HIV from a fatal disease to a 
chronic condition, quality of life (QoL) has emerged as a significant medical outcome in HIV 
management. Retaining HIV patients in long-term care so they achieve viral suppression is 
one of the key steps of UNAIDS’ 90-90-90 treatment target, yet it remains a major challenge 
in sub-Saharan Africa [6]. One important way to overcome this challenge is to ensure 
patients maintain a high QoL as they cope with their disease. Optimizing treatment and care 
based on the risk factors affecting QoL may lead to an improvement in the overall 
management of people living with HIV (PLHIV) and ensure they effectively stay in care, 
remain asymptomatic and no longer transmit the disease. 
Few studies investigating the determinants of QoL were conducted in western and 
central Africa. In Ghana, a prospective cohort of 152 PLHIV showed that food security and 
high diet diversity were associated with improvements in QoL scores over time [7]. In 
Nigeria, a cross-sectional study found that depressive disorder, lower socioeconomic status 
and education level and poor social support were associated with lower QoL scores [8]. 





lower QoL scores [9]. More recently, a study conducted in inland regions of Togo suggested 
that patients on ART or those with at least a secondary education, or who had disclosed their 
HIV status or lived in the rural region of Kara in northern Togo, had a significantly higher 
overall QoL [10]. However, no research has been conducted in Lomé, the Togolese capital 
and a dynamic, growing urban area. Moreover, no research has been conducted in a 
community healthcare setting, where patients receive social support such as financial 
assistance or sponsored meals in addition to long-term care, and are more likely to adhere to 
treatment because of the clinic’s patient-centered approach [11]. The current study was 
undertaken to assess the QoL of adult ART-treated HIV patients in such a clinic in Lomé, 
Togo, and identify the risk and protective factors associated with QoL. 
 
Methods 
Study Setting and Population 
We conducted a cross-sectional survey at Espoir Vie Togo (EVT) in July and August 
2019. EVT is a community health clinic and a non-governmental organization whose mission 
is to provide treatment and social support to PLHIV in Togo [12]. It currently manages 
approximately 3,500 patients and has clinics in Lomé, the capital, and in Aného and Sokodé.  
Study participants were consecutive men and women PLHIV 18 years or older who visited 
the clinic in July and August 2019. Eligibility criteria were: >=18 years, a confirmed HIV 
diagnosis and currently taking ART. Pregnant women were excluded. Patients were treated 
with an ART regimen consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) 





nucleoside reverse transcriptase inhibitor (NNRTI) (usually efavirenz [EFV]) or one protease 
inhibitor (usually atazanavir or atazanavir/ritonavir). 
 
Sample size 
We estimated the sample size based on a fixed model and R-squared increase for 
linear multiple regression. We assumed a medium population effect size, a power of 80%, a 
significance level of 5%, and 15 predictors. Using G*Power software Version 3.1.9.4, a 
sample size of 140 was generated [13]. 
 
Data Collection 
The principal investigator (HS), a clinical psychologist (JMAE), and a youth outreach 
coordinator (EH) interviewed the participants in French using the medical outcome study-
HIV health survey (MOS-HIV) before or after the doctor visit. Each survey lasted 10 to 15 
minutes. Approximately ten participants were interviewed daily, one at a time, in a private 
consultation room. Participants were given a 500 CFA (~ US $0.85) token as reimbursement 
for travel expenses. Prior to administering the survey, the following characteristics were 
collected from the medical records: gender, age, CD4 count, viral load, health status, 
serostatus (symptomatic or asymptomatic), treatment duration, ART regimen, line of 
treatment, treatment adherence and treatment-related side effects. Participants reported data 
on their education, employment, marital status, HIV status disclosure, social or family 
support, and alcohol use. Food insecurity was measured with Kleinman’s validated one-item 
screening question [14]. Body mass index (BMI) was calculated from height and weight 





consecutive doctor’s appointments and taking all pills in the week preceding an appointment. 
All data were collected on a password-protected tablet computer. 
 
Quality of Life Measure 
The MOS-HIV was used to assess QoL in our study population [15]. The French version of 
the survey was obtained from Mapi Research Trust (Lyon, France). The MOS-HIV is a 
disease-specific instrument that has been previously validated in various settings in sub-
Saharan Africa [16,17]. It includes 35 items investigating health transition (HT) and 10 
dimensions of QoL: general health perceptions (GH), pain (P), physical functioning (PF), 
role functioning (RF), social functioning (SF), energy/fatigue (EF), mental health (MH), 
health distress (HD), cognitive functioning (CF), quality of life (QL). Raw scores are 
computed then transformed to a 0 to 100 scale, with higher scores indicating better QoL. 
 
Ethical Approval 
Ethical approval to conduct this study was obtained from the Comité de Bioéthique pour la 
Recherche en Santé (031/2019/CBRS) in Togo and from the Committee for the Protection of 
Human Subjects of the University of Texas Health Science Center at Houston (HSC-SPH-19-
0357) in the United States. EVT granted their permission and provided logistics support for 
this study. All participants provided oral informed consent prior to study inclusion. 
 
Statistical Analysis 
Descriptive statistics were presented as proportions for categorical variables, and means and 





summary score (PHS) and a mental health summary score (MHS) were generated from the 
dimensions of QoL. A factor analysis with oblique rotation was performed to obtain factor 
score coefficients, which were used to compute the PHS and MHS scores [18]. The scores 
were standardized to a scale with a mean of 50 and standard deviation of 10. These 
standardized PHS and MHS scores were used as the dependent variables in two separate 
regression analyses. Cronbach’s alpha coefficients were calculated for dimensions with more 
than one item to measure the internal consistency of the questionnaire. An alpha greater than 
0.70 was selected to demonstrate adequate reliability and was considered satisfactory for 
comparisons. 
Two multiple linear regression analyses were fitted to determine the factors associated with 
QoL, one with PHS as the dependent variable, and the other with MHS as the dependent 
variable. All other measured variables were evaluated as candidate independent variables. 
Correlations among them were examined for multicollinearity. For each summary score 
(PHS and MHS), stepwise model selection was performed to determine the subset of 
variables best defining the relationship between the independent variables and the specific 
summary score under investigation. The variables included at the start of model selection 
were the ones found to have a p-value greater than 0.1 upon univariate analysis. The most 
parsimonious model for each summary score was selected and validated using a training and 
validation set. P <0.05 was set as the level of statistical significance. SAS software, Version 






Table 6. Baseline characteristics of 147 HIV patients at Espoir Vie Togo. 



















Unemployed or retired 
Employed part time 













BMI (kg/m2) 23.8 (5.5) 
HIV status disclosure 126 (87.5) 











Food insecurity 91 (61.9) 






CD4 count (cells/µl) 513.5 (350.2) 








Treatment duration (months) (n=144) 94.3 (60.3) 
Art regimen (n=140) 
3TC + TDF + EFV 














Adherence 135 (93.8) 
Side effects 33 (22.5) 
















Of the 157 patients who were approached for study participation, 147 agreed to 
participate, yielding a participation rate of 94%. 108 (73.5%) participants were female (Table 
1). The mean age (SD) was 43.2 (11.6) years and the mean (SD) duration of treatment was 
94.3 (60.3) months. Most patients had disclosed their HIV status to their partner or family 
(n=126; 87.5%), had family or social support (111; 75.5%), and suffered from food 
insecurity (91; 61.9%). 
 
Table 7. MOS-HIV dimensions of quality of life for 147 HIV patients at Espoir Vie Togo. 
Dimension Mean (SD) [range] Cronbach Alpha* 
General health 58 (22.6) [10-95] 0.78 
Pain 70.3 (23.3) [0-88.9] 0.77 
Physical functioning 90.8 (15.1) [25-100] 0.77 
Role functioning 88.1 (28.3) [0-100] 0.78 
Social functioning 93.2 (16.6) [20-100] - 
Energy/fatigue 61 (14.5) [10-95] 0.77 
Mental health 69 (13.9) [20-100] 0.76 
Health distress 83.2 (16.9) [30-100] 0.78 
Cognitive functioning 80 (15.3) [30-100] 0.79 
Quality of life 49 (21.9) [0-100] - 
Health transition 57.7 (22.6) [0-100] - 
PHS 80.7 (13.9) [28.3-96.8]  
MHS 66.7 (11.1) [30.7-87]  
*Cronbach’s alpha coefficients were calculated for dimensions with more than one item. 
Raw scores were transformed to a 0 to 100 scale. 




Quality of Life Scores 
The mean (SD) PHS and MHS scores were 80.7 (13.9) and 66.7 (11.1), respectively. 
The scores were relatively high on a 0-100 scale, and indicated an overall good QoL in the 





MOS-HIV survey. The internal consistency of the survey was high. The Cronbach’s alphas 
of the multi-item scales were adequate: GH (0.78), P (0.77), PF (0.77), RF (0.78), EF (0.77), 
MH (0.76), HD (0.78), CF (0.79). 
 
Factors Associated with Quality of Life 
For PHS, age, gender, food insecurity, ART adherence, side effects and self-evaluated 
health status were retained in the final model (Table 3). This subset of predictors explained 
21% of the variance in PHS (R-squared = 0.21). More specifically, lower PHS scores were 
associated with increasing age (p=0.01) and female gender (p=0.02), whereas higher PHS 
scores were associated with food security (p=0.045), not experiencing treatment-related side 
effects (p=0.03), and having an “excellent or very good” health status (p=0.003). For MHS, 
gender, education, food insecurity, ART adherence, family or social support and self-
evaluated health status were retained in the final model, which explained 30% of the variance 
in MHS (R squared = 0.30). Lower MHS scores were associated with female gender 
(p=0.02), having a primary level of education (p=0.05) and not having family or social 
support (p=0.006). On the other hand, higher MHS scores were associated with food security 











Table 8. Model selection of factors associated with quality of life in 147 HIV patients at 
Espoir Vie Togo 
Variable PHS 









Intercept 140.26 (60.17, 220.35) <0.001 3.36 (2.04, 4.69) <0.001 
Age (years) -1.01 (-1.82, -0.21) 0.014   
Gender (female) -25.33 (-46.40, -4.26) 0.019 -0.41 (-0.75, -0.074) 0.018 
Food security 19.68 (0.42, 38.94) 0.045 0.61 (0.32, 0.91) <0.001 
Adherence -25.31 (-63.23, 12.61) 0.189 -0.43 (-1.02, 0.16) 0.156 
Side effects (absent) 26.87, 3.29, 50.44) 0.026   
Health status (ref. Poor or mediocre) 
Excellent or very good 
Good 
 
58.51 (20.28, 96.73) 





0.95 (0.37, 1.53) 








   
-0.48 (-1.33, 0.36) 
-0.80 (-1.59, -0.0005) 





Social/family support   -0.46 (-0.78, -0.14) 0.006 




This cross-sectional study investigated the QoL of 147 ART-treated adult PLHIV in a 
community health clinic in Lomé, Togo. We measured relatively high PHS and MHS scores 
among patients treated at the clinic. Significant associations between physical and mental 
health summary scores and age, gender, education, food security, treatment-related side 
effects and self-evaluated health status were found. 
Physical and mental domains of QoL measured in the EVT population were relatively 
higher than those observed in previous comparable studies (i.e. studies conducted in sub-
Saharan Africa and using the MOS-HIV survey). Etenyi (2018) investigated a Kenyan 
outpatient population and reported PHS and MHS scores ranges between 60.14 (tenofovir 





(2018) measured PHS scores of 63.96 and MHS scores of 53.43 in a Rwandan patient 
population treated at public health centers [21]. It is likely that QoL scores in our population 
were higher because EVT is a medical center that supports its patients socially in addition to 
providing treatment in the long term. In fact, many patients receive clinic-sponsored meals 
the day of their doctor visit, while others receive financial assistance for their education or to 
pursue training opportunities. In addition, patients participate in a “causerie” (French for 
“informal talk”) prior to seeing the doctor and collecting their prescriptions. The “causerie” is 
a social worker-animated informal group talk providing patients with general disease 
information and coping mechanisms to help maintain their overall well-being in good state. 
All these patient-oriented elements lead to higher quality of care and better patient-provider 
relationship, which ultimately contribute to better patient outcomes and higher QoL, as 
suggested by a previous cross-sectional study [11]. 
As expected, several socio-demographic factors influenced the QoL of EVT patients. 
Age and gender, two well-known determinants of health, [22,23] were associated with PHS 
(age), and both PHS and MHS (gender). This confirms findings from previous research in 
western and central Africa [24,25]. Among HIV patients across 27 hospitals in Cameroon, 
Boyer (2012) reported lower physical component scores (PCS) but higher mental component 
scores (MCS) with increasing age, after adjusting for other socio-demographic and treatment-
related covariates. Thus, age was established as a major driver of QoL, as anticipated. The 
association was positive for MCS, most likely because of the more significant role social 
support plays in adolescents’ and young adults’ lives. However, the association was negative 





Africa, similar trends were observed [26-28]. In a Ugandan prospective cohort study, 
Mutabazi-Mwesigire (2015) reported that female gender was associated with lower MHS 
scores after adjustment [26]. In a cohort study also conducted in Uganda, Weiser (2012) 
reported lower PHS score in women treated at a regional referral hospital [27]. Although no 
specific explanation for these negative associations was reported in both studies, previous 
research has suggested that lower QoL measured in women may be attributable to gender 
differences in the reporting of psychological illnesses and somatic complaints [29,30]. 
Unsurprisingly, food insecurity was negatively associated with mental and physical 
health. This is predictable in sub-Saharan Africa, where it continues to be a daily concern for 
millions of people. One of the reasons explaining this association is the exacerbation of side 
effects caused by the lack of food to accompany ART [31]. This directly impacts the health 
outcomes and QoL of HIV patients who skip meals to afford their medication or do not 
adhere to treatment because of the lack of food. Our findings are similar to results from 
previous research in Ghana, Ethiopia and Uganda, where decreased QoL scores where 
measured in patients reporting food insecurity [32-34]. In a cross-sectional study of 664 HIV 
patients in Ethiopia, Mekuria (2015) specifically found that being able to obtain food with 
sufficient nutritional value was key to increasing physical, psychological, social, 
independence and environmental domains of QoL scores [33].  
Our study had several strengths. We investigated QoL in a region not well studied 
before and we provided insight on the QoL of adult PLHIV receiving ART in a patient-
oriented community clinic in Lomé. Moreover, we included a wide range of independent 





related side effects. Also, using a linear regression with model selection allowed us to control 
for confounding variables and select the variables best explaining the relationship between 
physical and mental domains of QoL and several risk or protective factors. This study also 
had limitations. The cross-sectional design limited our ability to establish a temporal 
relationship between the dependent and independent variables. Additionally, although the use 
of trained investigators instead of a self-administration approach to administer the MOS-HIV 
questionnaire was necessary due the lack of reading ability for several patients, it may have 
caused patients to inflate the positivity of their responses. As a result, QoL scores may have 
been overestimated due to social desirability bias. Also, our study was conducted in one 
community clinic in Lomé therefore our findings may not be generalizable to different 
settings. 
Overall, the social support provided by the clinic in addition to treatment is likely to 
positively impact patients’ QoL and overall wellbeing [11]. Future research should be 
extended to pediatric populations and potentially focus on comparing treatment satisfaction 
in patients treated in public hospitals and those treated in community health clinics. 
 
Conclusion 
This study suggests that PLHIV treated at a patient-oriented community health clinic 
in Lomé, Togo, had high physical health summary scores and moderately high mental health 
summary scores, as assessed by the MOS-HIV health survey. Age, gender, education, food 
security, treatment-related side effects and self-evaluated health status were significantly 





in a community health clinic, where the factors influencing QoL are also addressed during 
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Impact of Long-Term Care on the Quality of Life of HIV Patients in a Community 
Health Clinic in Togo: A Qualitative Study. 
 







Qualitative assessments of the quality of life (QoL) of HIV patients treated with 
antiretroviral therapy (ART) in western and central Africa are few in comparison to those in 
other parts of sub-Saharan Africa, Europe, and North America. Yet, valuable information can 
be discovered from patients’ individual experiences that can identify new variables not 
included in typical surveys. We interviewed 12 HIV patients receiving long-term ART at 
Espoir Vie Togo, a community health clinic providing social support, during July and August 
2019. All interviews were recorded, transcribed, and analyzed using a thematic analysis. 
Participants described good QoL as being in good health and being physically and mentally 
functional. Family, social and community support, the presence of a supporting individual, 
being on ART and food security were the main factors influencing QoL. In this cohort, 
participants experienced difficulties accepting their positive status, and often experienced 
perceived and enacted stigma. Ultimately, the positive effects of long-term care led 







The prevalence of people living with HIV (PLHIV) in sub-Saharan Africa has risen 
steadily in the last decade because of the increased access to life-saving antiretroviral therapy 
(ART) (1). Although the HIV/AIDS epidemic has declined since its peak in 2005, HIV 
prevalence in sub-Saharan Africa is still the highest in the world, with an estimated 25.6 
million PLHIV at the end of 2018 (2). In Togo, a small West African nation with a 
population of 7.9 million as of 2018, approximately 65,000 people received ART out of an 
estimated 110,000 PLHIV (3). The country made considerable progress towards limiting the 
spread of the epidemic, as shown by key indicators: in 2018, approximately 66% PLHIV 
knew their status, 89% of them received ART and 79% of the 21,000 PLHIV under ART 
who were able to have their viral load measured had viral suppression (4,5,6). These rates 
place Togo among the countries closest to reaching the 90-90-90 targets in sub-Saharan 
Africa, notably because of its small size, and because the epidemic has historically been 
moderate compared to more affected countries such as South Africa or Uganda. 
Nevertheless, the country-wide measures taken by health authorities to control the epidemic 
have been relatively successful so far (3,4). At the patient level, these milestones mean that 
HIV infection is no longer a death sentence and it is possible for newly infected individuals 
who initiate ART early and adhere to treatment to live a long and productive life (7). In fact, 
HIV has shifted from a fatal infection to a chronic disease when antiretrovirals became 
widely available in Togo after the “3 by 5” initiative was launched in 2003 to provide 3 
million doses of ART to people living with HIV (PLHIV) in low- and middle-income 





increased access to ART is to ensure patients are sufficiently empowered to adequately cope 
with their disease. Ideally, HIV patients should be able to maintain high rates of adherence to 
be virally suppressed over time and no longer transmit the disease (9). To this end, quality of 
life (QoL) has emerged as a significant follow-up outcome aiming at mitigating the 
challenges associated with lifelong treatment such as sustained adherence and economic 
difficulties (10). 
Several studies have investigated QoL among PLHIV across sub-Saharan Africa to 
determine the factors associated with QoL and to capture individual life experiences 
(11,12,13). Specifically, several public health studies in western and central Africa have 
taken a qualitative approach and given voice to HIV patients to deeply understand their 
experience (14-17). In Cameroon, Alomepe (2016) interviewed women living with HIV and 
described the challenges they faced. The emerging themes included the trauma of 
discovering one’s status, the difficulties of living with HIV, the lack of resource and support, 
and stigma (14). In addition to their illness, these issues affected their ability to perform their 
central role in their family. In a qualitive study conducted in Ethiopia, Alemayehu (2017) 
described the main aspects affecting QoL in visceral leishmaniasis and HIV coinfected 
males: liveability of the environment, utility of life, life ability of a person and appreciation 
of life (16). The study highlighted the multidimensional nature of QoL and the importance of 
starting specific programs to address these issues. In another qualitative study of newly 
infected patients conducted in Nigeria, Ogbuji (2010) found that psychological factors such 





factors influencing QoL, although certain life adjustments and psychological support allowed 
to better cope with the disease (17). 
Among factors affecting the QoL of PLHIV, stigma is frequently cited as one of the 
most enduring, despite general knowledge of the positive effects of ART on curbing the HIV 
epidemic (18). Several types of stigma have been described, including enacted and perceived 
stigma, both strongly acting as barriers to coping with the disease. Enacted stigma includes 
acts of discrimination and negative treatment from external sources towards PLHIV. 
Perceived stigma is the awareness and fear of being perceived negatively in society because 
of one’s HIV status, causing the avoidance of social experiences and opportunities (18). 
Previous research has indicated that perceived stigma has a negative impact on overall QoL, 
but it may vary according individual contexts and different settings (19). 
The World Health Organization describes QoL as an “individual perception”, and 
individual experiences vary according to social, cultural and religious contexts. Receiving 
sustained treatment also strongly influence individual experiences because of its strong and 
durable positive effects on the mental and physical health of HIV patients (20,21). There is 
more to learn about subjective factors associated with QoL shaped by personal, cultural or 
social experiences that are unique to each patient, especially in the context of a community 
health clinic, where patients are long-term ART recipients and experience strong social 
support in addition to receiving treatment (22). In such a population, certain underlying 
factors other than traditional socio-demographic and treatment-related factors significantly 
influence patients’ QoL and general wellbeing. Therefore, the objective of this study was to 





underlying and undiscovered indicators of quality of life, and better understand the life 
experiences of HIV patients receiving long-term ART in a community health clinic in Togo. 
 
Methods 
Study Setting and Population 
We conducted 12 semi-structured interviews of six female and six male patients 
receiving long-term ART in July and August 2019 at Espoir Vie Togo (EVT), a community 
health clinic and non-governmental organization treating and providing social support to HIV 
patients in Togo. EVT currently manages approximately 3,500 patients and has clinics in 
Lomé, the capital, and in Aného and Sokodé (22). Consecutive patients of the outpatient 
clinic in Lomé were asked to participate in the study prior to their doctor visit and 
participants received a 500 CFA (~ US $0.85) token as reimbursement for travel expenses. 
Eligibility criteria to participate in the study were being 18 years or older, having a confirmed 
HIV diagnosis and currently receiving ART for more than six months. 
 
Data Collection 
Face-to-face individual interviews were designed to give participants the opportunity 
to discuss their perceptions of QoL and factors influencing their QoL. The primary 
investigator (HS), assisted by a clinical psychologist with qualitative interview experience 
(JMAA), conducted the interviews, which took place in a private consultation room. All 
interviews were held in French, the official language and first language of most participants, 





recorder. Written notes were also taken by the study investigator during the discussion. All 
participants agreed to be recorded. 
Prior to starting the interview, the following characteristics were collected from the 
patient’s medical record: age, CD4 count, treatment duration, line of treatment, and 
adherence. Gender, education level, employment, marital status, HIV status disclosure, food 
insecurity and social or family support were self-reported. Adherence was defined as not 
missing two consecutive doctor’s appointments and taking all of one’s pills in the week 
preceding an appointment. Food insecurity was measured with Kleinman’s validated one-
item screening question (23). 
Based on an interview guide developed specifically for this study, the study 
investigator used a series of open-ended questions to encourage participants to share their 
experience and describe how their lives were affected by HIV (interview guide available 
from HS). The questions prompted participants to share their definition of QoL and describe 
their perceived determinants of QoL. The discussion was kept relatively informal to let 
participants engage in a conversation rather than in a question-answer session. This approach 
also encouraged participants to give honest answers. 
 
Data Analysis 
All interviews were transcribed and translated from French to English. We used 
pseudonyms throughout the study when quoting participants to maintain anonymity. Data 
analysis was performed using OpenCode version 4.0 (24). Data were analyzed following a 





content. The primary investigator (HS) used an open coding approach to capture the 
participants’ perception of QoL. After coding several transcripts, a set of codes was defined 
and subsequently used for similar recurring concepts. Additional codes were incorporated 
into the analytical framework as they were identified in subsequent transcripts. Several 
themes emerged and were examined at the latent level: the investigator sought to detect 
underlying ideas and concepts by analyzing patients’ words beyond what was said verbatim 
during the interviews. All themes were reviewed by an experience researcher who did not 




Ethical approval for this study was obtained from the Comité de Bioéthique pour la 
Recherche en Santé (031/2019/CBRS) in Togo, and from the University of Texas Health 
Science Center at Houston’s Committee for the Protection of Human Subjects (HSC-SPH-
19-0357) in the United States. Prior to study inclusion, all participants were read a script 
describing the study before providing oral informed consent. 
 
Results 
Twelve participants (6 women, 6 men) were enrolled in the study. All patients who 
were approached for study participation agreed to participate. The mean age was 32.6 years, 
and the majority had at least a secondary level of education and were single (Table 1). The 
mean duration of treatment was 96 months, and six participants were on their second line of 






Definition of a good quality of life 
Most participants described QoL as a combination of intertwined factors that resulted 
in a good QoL when all were functioning well. David told us: “To have a good quality of life 
is to be able to do any activity that would be expected of you. In other words, having the 
power to go about your business as usual without any constraints” (interview 1, David, 23 
years old). When specific features were discussed, “being in good health” was repeatedly 
mentioned as the main, if not the sole definition. Good QoL was also defined as overall 
wellbeing and being functional at the physical and mental levels. Justine mentioned that a 
good QoL was conditional on taking ART, thus acknowledging the importance of the role 
played by medications in improving symptoms and overall wellbeing (interview 3, Justine, 
18 years old). Kossi shared a different perspective on the definition of QoL that was outside 
of the usual scales: in his opinion, good QoL was about being free of problems, which 
negatively affected his mental health and prevented him from focusing on the important 












Table 9. Baseline Characteristics of 12 HIV Patients at Espoir Vie Togo. 






























HIV Status Disclosure 11 (91.7) 
Food Insecurity 8 (66.7) 








Adherence 12 (100) 
Family or Social Support 9 (75) 
Treatment Duration (months) (n=11) 96 (84.1) 
CD4 (cells/µL) (n=11) 613.9 (347.9) 
 
 
Determinants of QoL  
Living with HIV is challenging and imposes many constraints but for patients 
receiving long-term ART, general health improvements related to medication intake allow 
patients to focus more on their quality of life, and less on their health. At EVT, patients 
receive free treatment and are followed by psychologists, and this relieves part of the 
concerns related to being able to afford the therapy. Patients described the factors that 





and friends helped several patients cope with their disease. David described the positive 
influence he received from some members of his family after discovering he was HIV 
positive: “In my family, only my brothers and my sister knew my status. They were always 
watching after me, they always gave me advice. When I tried to break certain rules, they 
helped me get back on track.” Additionally, the medical and social support provided by EVT 
and its community played an important part in successfully managing the disease, as Grace 
stated: “I pray every day for EVT to continue their work because they work so well. They 
give us advice, they give us food” (interview 2, Grace, 44 years old). 
Sometimes, it was a specific person who played a key role in a patient’s ability to 
successfully cope with the disease. Friends and family members are often cited as supporting 
groups, but it could be a single individual who made a difference in this patient’s life. Leila 
said: “I have a friend (not a boyfriend), who knew my illness from the beginning. He is the 
first person I told. He really supported me. When he talks to me, I forget that I am sick” 
(interview 5, Leila, 40 years old).  
The benefits of taking ART was mentioned during several interviews. Because our 
population was long-term ART recipients, patients were maintained on stable regimens and 
they have had the opportunity to discuss and address potential side effects with the doctor. 
Kossi said: “Before taking ART, I got sick very often, but now, I only get sick once or twice 
in a three-month period.” Referring to his height, he added: “I even grew taller.” (interview 
10, Kossi, 19 years old). 
Food insecurity and the toxicity associated with taking ART without a meal were significant 





possible consequences on treatment adherence.  Linda reported: “I know that taking the 
treatment keeps me in good health. But taking the treatment means I must eat too, and if I 
don’t, there will be side effects. So sometimes, if I know I won’t eat, I won’t take my 
medications because of the side effects” (interview 4, Linda, 23 years old). 
Participants mainly described factors that contributed to improve their QoL such as family or 
social support and being under life-saving treatment. Because patients were receiving 
treatment for over 6 months and were on good health, they did not spontaneously think of 
negative factors, however, risk factors negatively associated with QoL were also discussed. 
Stigma is an enduring concern for PLHIV and it was brought up often enough during the 
interviews to emerge as a theme.  
 
Experiencing enacted and perceived stigma 
Study participants from both genders clearly understood the negative toll HIV had on 
their lives and they were able to easily communicate on their experiences. Several 
participants stated that they were negatively affected by the lack of awareness in the general 
population and they complained they were systematically judged and stigmatized although 
they were receiving ART and their disease was perfectly under control. Enacted stigma refers 
to acts of discrimination and negative treatment from external sources towards PLHIV. It was 
usually experienced outside of the close circle of friends or family knowing the participant’s 
HIV status. Perceived stigma originated within participants and they felt it when 
misinformation about HIV was circulated and they feared they would be treated negatively if 





negative person: sometimes, you cannot even stay among your friends because you may not 
feel well and be afraid people discover you have HIV” (interview 12, Ousmane, 50 years 
old). 
Like Ousmane, several participants indicated they had to hide their status to avoid stigma, 
discriminations or insults. Moreover, some participants said they were ashamed of their 
disease. Participants acknowledged it was harder to make platonic or romantic connections 
because of their status and perceived stigma, and their fear of rejection and enacted stigma. 
For example, Joel revealed: “I’m afraid sometimes to have romantic relationships, while an 
HIV negative person can live his life fully as he wants.” (interview 11, Joel, 18 years old). 
The lack of sexual partner was also brought up by Grace, who knew her status deteriorated 
her intimacy: “since I’ve had HIV, I do not make love anymore and it bothers me. When I 
find a partner, he tells me he does not want to use a condom so I have to refuse because I do 
not want that” (interview 2, Grace, 44 years old). 
Despite being under long-term treatment and having their disease under control, many 
participants are paralyzed by perceived stigma and fear the upsetting effects of enacted 
stigma. Some participants admitted they had lost friends or family because perceived and 
enacted stigma led them to avoid situations in which they could be shamed, some chose to 
stay away from people and preferred to be solitary. The desire to avoid stigma was so strong 
it led some to being abstinent, which some also described as being more “responsible” as we 







Becoming more “responsible” 
Being infected with HIV unexpectedly uncovered optimistic reactions and feelings of 
responsibility among several patients over time. In fact, some participants mentioned that 
they developed an increase in responsibility because of their disease, while others 
experienced a positive change in their behavior after being diagnosed and starting ART. 
Edem reflected on his past life and offered a powerful statement:  
Before my diagnosis, I lived a life not quite as one wishes, I had unprotected 
sex, I had multiple partners, I drank a lot of alcohol, and I smoked too. After 
the diagnosis, I stopped having unprotected sex and being with multiple 
partners. I no longer smoke or drink. I would tell a newly infected person to 
get tested, to follow the advice of doctors, to take the medication every day 
and at the times indicated, to eat well, and to protect himself during each 
intercourse.” (interview 9, Edem, 59 years old).  
This radical change in behavior was not infrequent in our population. At many occasions, 
being responsible vis-à-vis taking medications, and being responsible by adopting a healthier 
behavior was how participants chose to deal with their disease after several months under 
treatment. Speaking about the disease, Ousmane said: “You have to live with it. Live your 
life! Follow the advice of doctors, take your medicine in time, and you'll be happy like any 
other man. There are people damaging their own health because they tell themselves "I'm a 
sick person” (interview 12, Ousmane, 50 years old). It is likely that the patients in our study 
who become responsible and adopted positive attitudes were only able to do so because their 






Grief and difficulties of status acceptance 
Although maintaining good physical health was no longer a barrier for performing 
daily activities for participants in our sample of long-term care receivers, we collected a few 
testimonials that reflected persistent emotional distress and a feeling of grief for a way of 
living that was lost. In fact, Ousmane confessed that the hardest thing for him was the quest 
he pursued after discovering his positive status. He absolutely wanted to know how he 
became infected and after several months of unsuccessful attempts to discover what 
happened, he found peace only when he decided to let go and move on:  
At first, I tried to find out where it came from, but I could not find the answer. 
People warned me it could drive me crazy to absolutely want to know how it 
happened. Later, I understood it was true. I was devastated for a while, but I 
knew I had to give up to move forward, so this is my spirit now. (interview 
12, Ousmane, 50 years old).  
This feeling of grief was similar to what other patients experienced, as they struggled to 
accept and live with their newly discovered positive status. Kossi believed that one’s own 
perception of the disease determined their QoL, whether it was good or bad, so it was 
preferable to accept one’s condition and look forward: “often we, HIV patients, demean 
ourselves, and society does nothing but repeat the way we treat ourselves” (interview 10, 
Kossi, 19 years old). Marie also experienced difficulties when she discovered her status and 
saw her life change abruptly. She recalled: “I did not go out anymore. I was afraid to be sick 





Marie, 48 years old). These experiences show the emotional difficulties of discovering one’s 
positive status, and they suggest many participants have personal struggles before finding 
much needed support, sometimes through family and loyal friends, but often in community 
clinics like EVT. 
 
Discussion 
We investigated the life experiences and perceptions of QoL of twelve HIV patients 
receiving long-term ART in a community health clinic in Lomé, Togo. Participants defined 
good QoL as being in good health and being functional at a physical and mental level. The 
main factors influencing QoL were family, social and community support, the presence of a 
supporting individual, being on ART and food insecurity. The positive effects of long-term 
care often transformed patients and allowed some of them to become responsible vis-à-vis 
their disease. However, prior to developing positive attitudes over time, participants first 
experienced personal difficulties related to their newly discovered positive status, and they 
continue to face stigma, even after overcoming their personal struggles. 
Overall, our findings diverged from Ogbuji’s (2010), who reported predominantly 
negative feelings and experiences in a qualitative study of newly diagnosed HIV patients in 
Nigeria (17). In Ogbuji’s study, many participants reported that HIV was a punishment for 
their previous careless lifestyle, others were overwhelmed by discrimination, stigmatization 
and feelings of embarrassment. A few patients went as far as contemplating suicide. We note 
that Ogbuji’s research involved newly diagnosed patients while our study population 





our findings suggest that life experiences and QoL are likely to improve over time because of 
the positive effects of sustained antiretroviral treatment. Hence, Ogbuji’s population 
illustrated patients’ overall health impairment at the early stage of the disease whereas our 
population exemplified a possible positive evolution after several months of treatment. The 
better health outcomes and positive transformation of patients over time in our sample can 
also be attributed to the overall positive impact of EVT’s disease management strategy 
during patient follow up. In fact, the clinic has a very strong social component and its team of 
psychologists support patients in their daily needs (22).  
Our study confirms previous research suggesting experiences of enacted and 
perceived stigma are main concerns for patients and negatively affect QoL and overall 
wellbeing among PLHIV. In a mixed sample of patients, health personnel and care providers, 
Adedimeji (2010) reported that perceived stigma contributed to the non-disclosure of one’s 
status (15). Patients preferred limiting the disclosure of status to their close friends and 
family, and they sought treatment in places where they could remain anonymous. Women 
were disproportionally affected, as described by Alomepe (2016). They faced enacted stigma 
from their communities and even their families, because of the false perception that women 
with HIV engaged in immoral activities (14). In addition, they felt powerless as they lost 
their preponderant role as a pillar of society, as it is often the case for women in the sub-
Saharan African culture. Similar experiences with perceived stigma were described in our 
study because regardless of the setting, HIV patients felt powerless in front of an issue 
coming from external sources and driven by negative perception of the disease. Adedimeji’s 





as it is today. In the early 2010s, the general population still negatively perceived people 
living with HIV due to the lack of awareness, and it seems this trend is perduring today 
although it is unclear to what extent. 
Our findings are in accordance with those reported in Uganda by Mutabazi-
Mwesigire (2014), who conducted in-depth interviews at three and six months follow up with 
patients in an urban clinic as part of a prospective cohort study (25). The author reported that 
happiness was a strong indicator of good QoL and it was supported by good social networks 
and family. Happiness, and more generally, appreciation of life, reflected the positive attitude 
HIV patients can adopt to face their condition and improve their QoL, especially when they 
have been treated with ART for a long period of time. Although happiness was not 
specifically named in our study, many factors mentioned by our interviewees were proxies, 
specifically mental wellbeing.  
Several determinants of QoL described in this study were seldom investigated in 
previous research. Feelings of responsibility and the lack of sexual intercourse or the lack of 
sexual partner are often overlooked when considering HIV patients’ overall wellbeing, yet, 
those features were found to hinder several participants’ ability to feel whole. Additionally, 
family and social support are often cited as significant factors positively affecting QoL, but 
we noted that only one person can sometimes make a difference in a patient’s life and 
provide sufficient support when needed, especially if the patient and the confident were close 
prior to the disease, or if the person in need prefers to not disclose their status to other people 





It was not surprising that food insecurity was discussed by interviewees in our study, 
considering that it continues to be a major issue in developing countries. In Togo, an 
estimated 69% of households were living below the poverty line in 2015 (26). Food 
insecurity is thought to exacerbate ART-related side effects, and its effects on decreasing 
adherence to treatment in resource-limited settings have been previously demonstrated 
(27,28). Musumari (2013) reported on the negative impact of food insecurity on adherence 
among patients on ART, on ART-retreatment and those ultimately lost to follow-up. This 
issue was significant enough for UNAIDS to recommend stakeholders to associate food 
assistance programs to ART programs (29). 
Our study had several strengths. All participants who were approached for study 
participation agreed to participate, limiting selection bias. Also, because all participants 
agreed to be recorded, the content of the interviews was accurately transcribed, and it 
allowed the analysis to be based on complete and detailed material, supported by written 
notes. This study also had limitations. We interviewed patients who were followed up in a 
community health clinic providing social support, and we anticipated their overall wellbeing 
and QoL to be better than patients cared for in public hospitals. Also, the mean treatment 
duration of 96 months in our population indicates that our results are not applicable to newly-
diagnosed HIV patients. Finally, our sessions lasted approximately 15 minutes, which was 







This study assessed HIV patients receiving long-term care at a community health 
clinic with a strong social support component in Lomé, Togo, to better understand patients’ 
definitions of QoL, how HIV impacted their lives, and define the factors influencing QoL 
from their perspective. Despite the early difficulties and enacted and perceived stigma 
experienced by HIV patients, ART and other sociodemographic factors can improve their 
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We carried out this dissertation to synthesize current knowledge on the factors 
associated with QoL among ART-treated HIV patients in sub-Saharan Africa, and identify 
novel factors associated with QoL to provide foundations for the optimization of HIV care, 
based on the sociodemographic, clinical, behavioral, and psychological determinants of QoL. 
Our long-term goal was to provide robust evidence to help improve the overall management 
of people living with HIV. 
This dissertation confirmed the significant impact of certain factors associated with 
QoL such as ART, age, education level, gender, CD4 count, and mental health, but also 
encountered pertinent factors such as food insecurity, tuberculosis, and the lack of sexual 
partner. We highlighted several themes patients experience when coping with their disease 
such as experiencing enacted and perceived stigma, becoming more “responsible”, and 
facing difficulties accepting HIV status. 
One of the strengths of this dissertation was the focus on the sub-Saharan African 
experience, a severely affected region, where essential summary data on the factors 
associated with QoL was lacking. We chose to support our research with robust evidence 
collected from a systematic review and direct our efforts towards discovering new 
information collected in real-world settings. On the other hand, this dissertation was limited 
by its lack of generalizability. In fact, Togolese HIV patients treated at a community health 





limited by the small number of patients’ testimonies in our interviews which limited our 
ability to gain further insight on the life experience of HIV patients in this setting. 
Nevertheless, we are confident that this dissertation addressed current gaps in 
knowledge and opened the door to future research. We reported that the QoL scores of HIV 
patients treated at a community health clinic in Togo were relatively higher compared to 
equivalent studies in Kenya and Rwanda. Future research may be conducted to attempt a 
comparative analysis evaluating the QoL and treatment satisfaction of patients treated at 
Espoir Vie Togo, or other non-governmental organizations, versus patients treated at a public 
healthcare facility, which lack the social support component provided at Espoir Vie Togo and 
similar facilities. Furthermore, additional research may be conducted on certain factors 










Appendix A: Ovid Medline Search Strategy 
 
1. HIV-2/ or HIV/ or HIV Seropositivity/ or HIV-1/ 
2. hiv infections/ or acquired immunodeficiency syndrome/ 
3. (hiv or aids).ti,ab,kw. 
4. 1 or 2 or 3 
5. "Quality of Life"/ 
6. ("Quality of Life" or QOL or HRQoL or "Health-related quality of life").ti,ab,kw." 
7. 5 or 6 
8. africa/ or "africa south of the sahara"/ or africa, central/ or cameroon/ or central african 
republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or 
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ 
or somalia/ or south sudan/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or 
botswana/ or lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ 
or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote 
d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ 
or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
9. (Angola or benin or botswana or burkina faso or burundi or cameroon or cape verde or 
"central african republic" or chad or congo or "cote d'ivoire" or djibouti or eritrea or ethiopia 
or gabon or gambia or ghana or guinea or kenya or lesotho or liberia or malawi or mali or 
mauritania or mozambique or namibia or niger or nigeria or rwanda or senegal or "sierra 
leone" or somalia or saharan or sudan or swaziland or tanzania or togo or uganda or zambia 
or Zimbabwe).ti,ab,kw. 
10. 8 or 9 






Appendix B: PubMed Search Strategy 
 
1. (HIV-2[mesh] or HIV[mesh] or HIV Seropositivity[mesh] or HIV-1[mesh]) OR (hiv 
infections[mesh] or acquired immunodeficiency syndrome[mesh]) OR (hiv[tiab] or 
aids[tiab]) 
2. ("Quality of Life"[mesh]) OR ("Quality of Life"[tiab] or QOL[tiab] or HRQoL[tiab] or 
"Health-related quality of life"[tiab]) 
3. (africa[mesh] or "africa south of the sahara"[mesh] or africa, central[mesh] or 
cameroon[mesh] or central african republic[mesh] or chad[mesh] or congo[mesh] or 
"democratic republic of the congo"[mesh] or equatorial guinea[mesh] or gabon[mesh] or 
africa, eastern[mesh] or burundi[mesh] or djibouti[mesh] or eritrea[mesh] or ethiopia[mesh] 
or kenya[mesh] or rwanda[mesh] or somalia[mesh] or south sudan[mesh] or sudan[mesh] or 
tanzania[mesh] or uganda[mesh] or africa, southern[mesh] or angola[mesh] or 
botswana[mesh] or lesotho[mesh] or malawi[mesh] or mozambique[mesh] or namibia[mesh] 
or south africa[mesh] or swaziland[mesh] or zambia[mesh] or zimbabwe[mesh] or africa, 
western[mesh] or benin[mesh] or burkina faso[mesh] or cape verde[mesh] or cote 
d'ivoire[mesh] or gambia[mesh] or ghana[mesh] or guinea[mesh] or guinea-bissau[mesh] or 
liberia[mesh] or mali[mesh] or mauritania[mesh] or niger[mesh] or nigeria[mesh] or 
senegal[mesh] or sierra leone[mesh] or togo[mesh]) OR (Angola[tiab] or benin[tiab] or 
botswana[tiab] or burkina faso[tiab] or burundi[tiab] or cameroon[tiab] or "cape verde"[tiab] 
or "central african republic"[tiab] or chad[tiab] or congo[tiab] or "cote d'ivoire"[tiab] or 
djibouti[tiab] or eritrea[tiab] or ethiopia[tiab] or gabon[tiab] or gambia[tiab] or ghana[tiab] or 
guinea[tiab] or kenya[tiab] or lesotho[tiab] or liberia[tiab] or malawi[tiab] or mali[tiab] or 
mauritania[tiab] or mozambique[tiab] or namibia[tiab] or niger[tiab] or nigeria[tiab] or 
rwanda[tiab] or senegal[tiab] or "sierra leone"[tiab] or somalia[tiab] or saharan[tiab] or 







Appendix C: Embase Search Strategy 
 
1. (HIV-2 or HIV or HIV Seropositivity or HIV-1) OR (hiv infections or acquired 
immunodeficiency syndrome) OR hiv.ab,kf,ti. OR aids.ab,kf,ti. 
2. Quality of Life.ab,kf,ti. OR QOL or HRQoL OR health-related quality of life 
3. ‘sub-saharan africa‘ or ‘africa south of the sahara’ or africa, central or cameroon or 
‘central african republic’ or chad or congo or ‘democratic republic of the congo’ or 
‘equatorial guinea’ or gabon or ‘africa, eastern’ or burundi or djibouti or eritrea or ethiopia or 
kenya or rwanda or somalia or south sudan or sudan or tanzania or uganda or ‘africa, 
southern’ or angola or botswana or lesotho or malawi or mozambique or namibia or south 
africa or swaziland or zambia or zimbabwe or ‘africa, western’ or benin or burkina faso or 
cape verde or cote d ivoire or gambia or ghana or guinea or guinea-bissau or liberia or mali 

















Appendix D: PsycINFO Search Strategy 
 
1. HIV-2/ or HIV/ or HIV Seropositivity/ or HIV-1/  
2. hiv infections/ or acquired immunodeficiency syndrome/  
3. (hiv or aids).ti,ab 
4. 1 or 2 or 3  
5. "Quality of Life"/  
6. ("Quality of Life" or QOL or HRQoL or "Health-related quality of life").ti,ab 
7. 5 or 6 
8. africa/ or "africa south of the sahara"/ or africa, central/ or cameroon/ or central african 
republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or 
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ 
or somalia/ or south sudan/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or 
botswana/ or lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ 
or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote 
d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ 
or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/  
9. (Angola or benin or botswana or "burkina faso" or burundi or cameroon or cape verde or 
"central african republic" or chad or congo or "cote d'ivoire" or djibouti or eritrea or ethiopia 
or gabon or gambia or ghana or guinea or kenya or lesotho or liberia or malawi or mali or 
mauritania or mozambique or namibia or niger or nigeria or rwanda or senegal or "sierra 
leone" or somalia or saharan or sudan or swaziland or tanzania or togo or uganda or zambia 
or zimbabwe).ti,ab 
10. 8 or 9 
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